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Resumo 
Helicobacter pylori (H. pylori), uma bactéria gram-negativa espiralada, é um dos agentes 
infeciosos mais comuns em todo o mundo, colonizando a mucosa gástrica de mais de 50% da 
população mundial e cerca de 80-90% da população Portuguesa. 
Devido à sua motilidade flagelar e capacidade para criar um microambiente favorável, a 
H. pylori é capaz de persistir no ambiente acídico do estômago e aderir ao epitélio gástrico, 
estabelecendo com sucesso a infeção. A adesão é mediada por moléculas na superfície 
bacteriana, denominadas adesinas, capazes de reconhecer glicanos expressos na superfície de 
células epiteliais gástricas e na camada de muco que reveste a mucosa gástrica. A longo 
prazo, a presença da bactéria aumenta significativamente o risco de desenvolver várias 
complicações gástricas, sendo uma delas o cancro gástrico. 
Atualmente, as terapias convencionais contra a infeção causada pela H. pylori baseiam-se 
na administração combinada de dois antibióticos e um inibidor da bomba de protões. No 
entanto, o tratamento é ineficaz em 20% dos casos, deixando cerca de 140 milhões de 
doentes em todo o mundo sem tratamentos alternativos. As taxas de cura têm vindo a 
diminuir ao longo dos anos, principalmente devido à resistência bacteriana aos antibióticos e 
à baixa adesão dos pacientes. 
Neste contexto, várias terapias alternativas estão sob investigação. O quitosano, um 
polímero catiónico natural e não tóxico, tem sido bastante investigado como uma ferramenta 
contra infeções gástricas, principalmente devido à sua biocompatibilidade e 
biodegradabilidade, juntamente com as suas propriedades anti- bacterianas e mucoadesivas. 
Apesar da crescente aplicação de sistemas de encapsulação baseados em quitosano, a 
utilização de microesferas de quitosano como um sistema de ligação à H. pylori foi também 
proposta, onde, após administração oral, as microesferas são capazes de capturar e remover 
bactérias do estômago, tirando partido da sua capacidade mucoadesiva/anti-bacteriana. 
Embora encontradas livremente na camada de muco, as bactérias são também 
encontradas aderidas ao muco e à superfície de células epiteliais nas fovéolas gástricas 
(invaginações do estômago). A estabilidade das microesferas de quitosano em meio ácido, 
quando reticuladas com genipina, foi já demonstrada, bem como a sua capacidade para se 
ligar e remover a H. pylori aderente às células gástricas. Estudos em secções 2D de mucosa 
gástrica humana mostraram que as fovéolas gástricas têm aproximadamente 70 μm de 
largura, o que pode dificultar a penetração das microesferas anteriormente desenvolvidas, 
com diâmetro de cerca de 170 µm, e a remoção das bactérias instaladas no interior das 
fovéolas. É então sugerido que, de modo a alcançar as bactérias e removê-las do estômago, 
as microesferas devem apresentar um tamanho menor do que o descrito anteriormente. 
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Assim, o objetivo deste projeto consiste no desenvolvimento de microesferas com cerca 
de 50 µm, pequenas o suficiente para penetrar as fovéolas da mucosa gástrica. Microesferas 
de quitosano foram produzidas e caracterizadas, e a sua penetração nas fovéolas gástricas de 
ratinho e humanas foi avaliada, bem como a sua capacidade de adesão à H. pylori. 
Para esse propósito, microesferas de quitosano foram produzidas através de três sistemas 
diferentes, nomeadamente o sistema eletrostático, de pressão co-axial e aerodinâmico. 
Técnicas baseadas em microscopia ótica (Microscópio Ótico e IN Cell Analyzer) e na difração 
de laser (Mastersizer) foram usadas para caracterizar as microesferas de quitosano 
relativamente ao seu tamanho e morfologia. 
Um modelo ex-vivo de estômagos frescos de ratinho foi utilizado para otimizar a 
marcação com fluorescência da mucosa gástrica. Diferentes marcadores foram testados, 
revelando DAPI (amostra fixa) e o marcador de membrana CellMaskTM Deep Red (fresco) com 
bons marcadores para a visualização da mucosa gástrica. As microesferas de quitosano com 
um diâmetro médio de 20 µm foram produzidas com sucesso e incubadas com as mucosas 
gástricas de ratinhos e humana. Microscopia de confocal revelou a presença de microesferas 
em diferentes planos da mucosa, confirmando assim a sua capacidade de penetrar as fovéolas 
gástricas.  
Além disso, a incubação da H. pylori com as microesferas revelou a sua capacidade de 
aderir à superfície das partículas.  
Em conclusão, os resultados sugerem as microesferas de quitosano desenvolvidas como 
uma ferramenta promissora para explorar o tratamento de infeções causadas por H. pylori. 
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Abstract 
Helicobacter pylori (H. pylori), a spiral-shaped gram-negative bacterium, is one of the 
most common infectious agents in the world, colonizing human gastric mucosa of over 50% of 
the world’s population and 80-90% of the Portuguese population.  
Due to its flagellar motility and ability to create a favourable microenvironment, H. 
pylori is able to persist in the stomach acidic environment and attach to the gastric 
epithelium, establishing the infection. Its adherence is mediated by molecules (adhesins) on 
the bacterial surface able to recognize glycans expressed on the surface of gastric epithelial 
cells and mucus layer lining the gastric mucosa. Long-term carriage significantly increases 
the risk of developing several gastric-specific complications, going from gastritis to gastric 
cancer. 
Current H. pylori infection conventional therapies rely on a concomitant administration 
of two antibiotics and proton pump inhibitor. However, the treatment is inefficient in 20% of 
the cases, leaving nearly 140 million patients worldwide without any alternative treatment 
option. The cure rates have been declining over the years, mostly due to bacterial resistance 
to antibiotics and poor patient compliance.  
In this context, several alternative therapies are under investigation. Chitosan, a 
natural-nontoxic cationic polymer, has been thoroughly investigated as a tool against gastric 
infections, mainly due to its biocompatibility and biodegradability coupled with its anti-
bacterial and mucoadhesive properties. Despite the growing application of chitosan-based 
encapsulation systems, the use of chitosan microspheres as a H. pylori binding system has 
also been proposed, where, after oral administration, microspheres are able to capture and 
remove bacteria from the stomach, taking advantage of their muco/bacterial adhesive 
capacity. 
Although found free-swimming in the mucus layer, bacteria are also found adherent to 
the mucus layer and the surface of epithelial cells in gastric foveolae (stomach 
invaginations). The stability of chitosan microspheres in acidic environment, when 
crosslinked with genipin, has been demonstrated as well as their ability to bind and remove 
adherent H. pylori from gastric cells. Studies using 2D sections of human gastric mucosae 
have shown that human stomach foveolae are ~70 µm wide, which might hamper the 
penetration of previously developed chitosan microspheres, with a diameter around 170 µm, 
and the removal of the bacteria living within the foveolae. Therefore, it is suggested that 
the microspheres should be smaller than the previously developed in order to reach bacteria 
and remove them from the stomach. 
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The aim of this project is to develop chitosan microspheres with a diameter around 50 
µm, small enough to penetrate gastric foveolae and remove bacteria adhered inside. The 
microspheres were produced and characterised, and their penetration into mice and human 
gastric foveolae as well as their ability to adhere onto H. pylori evaluated. 
For this purpose, chitosan microspheres were produced by three different systems, 
namely high voltage electrostatic, co-axial air stream and aerodynamically driven systems. 
Techniques based on optical microscopy (Optical Microscopy, IN Cell Analyzer) and laser 
diffraction (Mastersizer) were used to characterize chitosan microspheres regarding size and 
morphology.   
An ex-vivo model using fresh mice stomach samples was used to optimize the 
fluorescence labelling of gastric mucosa. Different dyes were explored, revealing DAPI (fixed 
sample) and CellMaskTM Deep Red plasma membrane (fresh) stain as good gastric mucosa 
markers. Chitosan microspheres with an average diameter of 20 µm were successfully 
produced and incubated with mice and human gastric mucosa. Confocal microscopy revealed 
their presence in different plans of the mucosa, thus confirming their ability to penetrate 
the gastric foveolae.  
Moreover, H. pylori incubation with chitosan microspheres has revealed their ability to 
adhere to the surface of the particles. 
In conclusion, results suggest chitosan microspheres developed as a promising tool to 
explore as H. pylori infection treatment. 
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Chapter 1  
Introduction 
1.1 Stomach and its mucosal surface 
The digestive tube is a musculomembranous tube, with about 9 metres long, extending 
from the mouth to the anus, and lined throughout its entire extent by mucus membrane [1]. 
The stomach is the first intra-abdominal and the most dilated part of the gastrointestinal 
tract, and is situated between the end of the esophagus and the beginning of the small 
intestine, the duodenum [1]. 
It is a muscular, highly vascular, distensible bag-shaped organ, divided in four main 
different regions [1]: cardia, fundus, body and pylorus. The cardia, where the contents from 
the oesophagus are deposited, is the acute angle between the abdominal esophagus and the 
fundus of the stomach, the upper curvature. The body (corpus) corresponds to the bigger 
region of the stomach leading to the pyloric antrum, which is the lower section narrowing 
toward the pylorus, which occupies the distal one quart of the stomach, surrounded by the 
smooth muscle pyloric sphincter [2]. 
The wall of the stomach consists of four layers: serosa, muscularis, submucosa and 
mucosa, together with vessels and nerves (Figure 1) [1]. The outermost layer of the stomach 
is the serosa, a thin serous membrane made of simple squamous epithelial tissue and areolar 
connective tissue. The muscularis layer is composed by 3 layers of smooth muscle tissue 
arranged with its fibers running in 3 different directions: longitudinal external, circular media 
and oblique internal. The submucosa is made of various connective tissues, blood vessels, and 
nerves, and surrounds the mucosa, the innermost layer of the stomach. The stomach mucosa 
contains simple columnar epithelium tissue, a layer of loose connective tissue of lamina 
propria, and thin layer of smooth muscle, the muscularis mucosae. The surface of the 
epithelium is connected via the foveolae (gastric pits) and neck region to the deeper gastric 
glands [3]. These foveolae contain exocrine cells able to produce mucus and secrete digestive 
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enzymes and hydrochloric acid into the lumen of the stomach, creating an environment with 
an acidic pH, able to kill many of the bacteria present in the stomach [4].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The mucus layer is a biochemically complex medium, highly hydrated and rich in high 
molecular weight and heavily glycosylated glycoproteins known as mucins, antimicrobial 
peptides, immunoglobulins and other intestinal proteins [6]. The alkaline and viscous mucus 
is continuously secreted by the mucous superficial cells and neck cells, being its function to 
protect gastric epithelial cells against chemical, enzymatic, microbial and mechanical harm 
[7]. Mucins act as diffusion barrier to acidic HCl instilled into the lumen of the stomach and 
alkaline bicarbonate ions secreted by the gastric epithelium, causing the stomach pH to vary 
between pH 1.2–2.5 in the gastric lumen and pH ~7.4 near the epithelial surface [8]. 
1.2 Helicobacter pylori colonization 
Helicobacter pylori (H. pylori), spiral-shaped gram-negative bacteria, is one of the most 
common infectious agents, colonizing the gastric mucosa of over 50% of the human population 
[1]. H. pylori infection is the strongest known risk factor for gastroduodenal ulcer 
development, present in 60–80% of gastric ulcers and being as well causally (1-3%) related to 
gastric adenocarcinoma [2]. Infection induces an inflammatory response that does not 
eradicate the bacterial colonization, but which instead persists for the lifetime of the 
individual [3]. However, less than 20% of infected individuals have clinical symptoms [4]. 
The risk of serious clinical outcomes is related to interactions between the host, bacteria 
and environment [2]. In general, the host is able to eliminate the bacteria through gastric 
acidity, peristaltic movements and mucus continuously secreted from glands of the epithelial 
cell, which pushes bacteria toward the luminal surface, inhibiting the adhesion and 
colonization of the bacteria in the gastric mucus layer [5]. However, H. pylori have evolved 
intricate mechanisms to avoid the bactericidal acid in the gastric lumen and to survive near 
to, to attach to, and to subvert the human gastric epithelium and immune system [2]. The 
hostile environment features are overcome by virulence factors that create a micro 
Figure 1 - Structures of human stomach and gastric mucosa [5]. 
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environment favourable to its survival. The bacteria is then able to escape the acidic pH of 
the stomach (pH 1.2–2.5) crossing the mucus layer that covers and protects the gastric cells, 
reaching the gastric epithelium where the pH is more neutral (pH ~7.4). This is achieved due 
to its flagellar motility and secretion of urease, which converts endogenous urea into 
ammonia and carbon dioxide, thereby buffering gastric acid in the immediate vicinity of the 
organism [6]. 
Most H. pylori are frequently found moving in the mucus layer, but some bacteria actually 
adhere to the surface of gastric epithelial cells. Schreiber et al. [7] revealed that H. pylori 
colonizes mainly a thin mucus layer located 0-25 µm above the tissue surface, being the 
majority of H. pylori (88%) found within the first 15 µm, with 30% either swimming in the 
layer immediately adjacent to the epithelial cells (0-5 µm) or adhering to them. 
Non-adherent H. pylori are able to cause a direct injurious effect on gastric epithelial 
cells, which is amplified by production and release of a vacuolating cytotoxin, VacA (Figure 2) 
[8]. This secreted protein is able to induce multiple structural and functional alterations in 
cells, such as the formation of large intracellular vacuoles [9,10] and the increase in 
membrane permeability [11]. This event occurs through its insertion in cell membranes, 
which in turn leads to the formation of anion selective channels [12]. In addition, VacA 
stimulates apoptosis in gastric epithelial cells [13], by inducing the release of cytochrome c 
from the mitochondria, therefore activating caspase 3. The inhibition of the expansion of T 
cells, thereby allowing H. pylori to evade the adaptive immune response, is also attributed to 
VacA protein action [14]. 
Nevertheless, attachment is a prerequisite for a successful microbial colonization of 
epithelial surfaces. Interaction between the bacteria and the cells is mediated by molecules 
on the bacterial surface, adhesins, which recognize proteins or glycoconjugates expressed on 
the surface of gastric epithelial cells and also in the mucus layer lining the gastric mucosa 
[6]. H. pylori express adhesins that confer intimate adherence to the gastric epithelium 
where the bacteria can gain easy access to nutrients from host tissues [15]. These adherence 
properties protect the bacteria from the extreme acidity of the gastric lumen and 
displacement from the stomach by forces such as those generated by peristalsis and gastric 
emptying [16]. Two carbohydrate structures in surface mucus cells serve as specific ligands 
for H. pylori adhesins: Lewis blood group antigens, such as Lewis b (Leb), mainly distributed 
in the epithelium surface, and Lewis x (LeX), located deeper in the mucus [5]. The blood 
group antigen-binding adhesin (BabA) was shown to recognize the Leb while sialic acid-binding 
adhesin (SabA) mediates the adherence of H. pylori to inflamed gastric mucosa by binding 
sialylated carbohydrate structures such as sialyl Lewis x (sLex)  [5,6].  
Apart from adhesins and VacA protein, the cytotoxin-associated gene (cagA) is another 
genetic determinant involved in H. pylori virulence [17]. CagA antigen, gene inserted in the 
H. pylori cag pathogenicity island (PAI), is an H. pylori strain-specific factor, which increases 
the risk for development of distal gastric cancer [18], by inducing strong gastric inflammation 
[19]. Subsequent to epithelial cells adherence, H. pylori is able to assemble a type IV 
secretion system, encoded by the cag pathogenicity island (PAI), which translocates the CagA 
protein into gastric epithelial cells  [19,20]. Once inside the former epithelial cells, CagA is 
tyrosine-phosphorylated, however both phosphorylated and nonphosphorylated CagA can 
cause numerous cellular alterations [20]. 
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Figure 2 - Factors that influence the interactions of H pylori with human gastric mucosa [21]. The 
secretion of VacA protein by nonadherent bacteria can affect several cell types, including gastric 
epithelial cells and T cells [22]. Adhesins, namely BabA and SabA, mediate the binding of H. pylori to 
the gastric epithelial cells and mucus [16]. The adherent bacteria are able of assemble a type IV 
secretion system that allows the entrance of CagA protein into the gastric cells conducting to cellular 
alterations [20]. 
  
H. pylori capability of expressing these aforementioned factors will conduct to strains 
with different levels of pathogenicity, which will be determinant for the interaction between 
the bacteria and the human host [23]. 
1.3 Current treatments 
H. pylori eradication treatments require not only antibiotics to kill the bacteria, such as 
amoxicillin, clarithromycin or metronidazole, but also anti-acid medications, particularly 
proton pump inhibitors (PPI) such as omeprazole, rabeprazole, lansoprazole,  to increase the 
environmental pH, therefore ensuring antibiotics stability  within stomach [2]. 
Current available regimens to treat H. pylori infection rely on a triple treatment, which 
includes PPI-clarithromycin and amoxicillin or metronidazole [24–26]. Nevertheless, the most 
recent data have recognized lack of efficiency on the former treatment, often allowing the 
cure of only a maximum of 70% of the patients, which is less than the 80% rate aimed [26] 
and expected for an infectious disease [27]. The administration of the three antibiotics 
together with a PPI (non-bismuth quadruple therapy) has also been considered [28] as well as 
the bismuth-containing quadruple therapy following the development of a gallenic 
formulation including bismuth salts, tetracycline and metronidazole in the same pill [29].   
The Maastricht IV/Florence Consensus Report [24] has stated that PPI-clarithromycin-
containing triple therapy without prior susceptibility testing should be abandoned when the 
clarithromycin resistance rate in the region is more than 15-20%. Moreover, recommended 
regimens vary slightly between areas with low or high clarithromycin resistance. Regarding 
the former case, clarithromycin-containing treatments are recommended for first-line 
empirical treatment, with bismuth-containing quadruple therapy being also an alternative. In 
order to increase the efficacy of triple therapy, some modifications may be implemented:  a 
higher dose (twice a day) of PPI can be used and extending the duration of PPI-
clarithromycin-containing triple therapies from 7 to 10-14 days improves the eradication 
success by about 5% and therefore may be considered as well. PPI-clarithromycin-
metronidazole (PCM) and PPI-clarithromycin-amoxicillin (PCA) regimens are equivalent, and 
therefore metronidazole can be used instead of amoxicillin as the second antibiotic. After 
failure of a PPI-clarithromycin-containing treatment, either a bismuth-containing quadruple 
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therapy or levofloxacin-containing triple therapy is recommended. Concerning areas of high 
clarithromycin resistance, bismuth-containing quadruple therapies are recommended for 
first-line empirical treatment. If this regimen is not available, sequential treatment or a non-
bismuth quadruple therapy is recommended. In case first line regimen fails, levofloxacin 
containing triple therapy is recommended. In both areas, after failure of second-line therapy 
and whenever possible, the treatment should be guided by antimicrobial susceptibility 
testing. 
Particularly, for patients with penicillin allergy, in areas of low clarithromycin resistance, 
for a first-line treatment, a PPI-clarithromycin-metronidazole combination may be prescribed 
while in areas of high clarithromycin resistance, the bismuth- containing quadruple therapy 
should be advised [24]. 
1.4 Reasons for unsuccessful treatments 
The low rate of success in H. pylori is manly related to: (a), poor penetration and (b) 
antibiotic degradation, (c) H. pylori resistance to the antibiotics, (d) recurrence of infection 
and (c) poor compliance.  
The mucus membrane and H. pylori ability to survive in the deep gastric mucosa and in 
the intercellular space between epithelial cells have been proved to limit the access of the 
drugs to the site of action [5,30], causing poor penetration of the antibiotics [5], therefore 
reducing the concentration of antibiotics at the site of action.  
Antibiotic degradation is also a problem leading to unsuccessful treatments, since to act 
effectively against H. pylori, the released antibacterial agents must remain stable in the 
acidic environment of the gastric lumen [31], in order to reach the site of infection in their 
active form [32]. Their proved instability in stomach environment [31–35], reduces the 
bioavailability of the antibiotics reducing their effect on H. pylori, therefore preventing the 
complete eradication of the bacteria [5,30], even in the presence of PPIs [33,36].  
The difficulty of establishing a standard treatment regimen worldwide has also been 
referred as an obstacle to the successful treatment of H. pylori. A significant variation in the 
resistance to antibiotics in H. pylori has been reported [37], especially to clarithromycin, 
which global resistance rate has increased in Europe from 9% in 1998 [38] to 17.6% in 2008-9 
[39]. Therefore, knowledge of previously prescribed antibiotics in the population and 
information about the presence of resistance in the region or other similar areas provides a 
basis for the prescription of the treatment, suggesting the use of some antibiotics over 
others. As H. pylori often becomes resistant when single antibiotics are used for other 
infections, discussion with the patient and identification of which antibiotics have been used 
in the past may be useful to gather information about possible resistance. Their prior use 
might exclude them from specific H. pylori therapy [2]. 
In addition, H. pylori treatment raises some concerns due to the possible recurrence of 
infection [37]. In fact, despite the fact that re-infection after eradication is rare in developed 
countries, in developing countries is still relatively high, around 13% [40]. 
Poor patient compliance due to the dosage regime [41] and due to adverse effects such as 
diarrhea, nausea, and retching [36] have also been considered as limited factors [24]. 
Overall, it has been estimated that eradication therapy is unsuccessful in nearly one in 
five patients [42], leaving potentially around 140 million people without an alternative 
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treatment [43]. Despite the large number of studies, an optimal therapeutic regimen for the 
treatment of H. pylori has not yet been defined, and therefore, alternative therapies are 
required. 
1.5 Alternative therapies 
Alternative therapeutic approaches able to overcome the aforementioned problems have 
been considered. Special attention has been given to the antimicrobial activity of certain 
non-antibiotic compounds, such as polyunsaturated fatty acids [44], vaccines developed 
against H. pylori [45], inhibitors of virulence factors [17,46] and other molecules, such as 
polyphenols [47], able to reduce the activity of the bacteria, therefore maximizing the 
success of the treatment. Some of the strategies may be applied as co-adjuvants of the 
current available therapies [48], leading to an improved outcome. Encapsulation of drugs for 
local delivery has been another extensively studied approach seeking to improve antibiotics 
effect against H. pylori[49]. 
 Certain polyunsaturated fatty acids (PUFA) have been considered due to their inhibitory 
effect on bacterial growth [50]. Particularly, docosahexaenoic acid (DHA), an n-3 
polyunsaturated fatty acid (n-3 PUFA), has been identified as an antibacterial agent, due to 
its ability to inhibit H. pylori growth in vitro and in vivo by reducing gastric mucosa 
colonization [48], by altering the bacterial membrane protein composition [44]. The 
recurrence of H. pylori infection in the mouse model was shown to decrease as a result of the 
combination of DHA with standard treatments. 
Given the worldwide variation of H pylori infection prevalence, which in 2010 ranged 
between 7% and 87% [51], a vaccination strategy would be a valuable option to fight H. pylori 
infection [45,52,53]. However, despite several attempts to develop an H. pylori vaccine for 
humans, progress has been slow. Patent WO 2008/105740 A1 (A New immunoglobulin against 
Helicobacter pylori) describes the preparation of antibodies against the H. pylori BabA 
adhesin and suggests their application in the development of H. pylori passive vaccination. 
However, its action remains unproven. 
Virulence factors inhibitors have also been considered in this sense. For instance, being 
urease essential for the survival of H. pylori [54], drugs such as acetohydroxamic acid (AHA), 
a specific urease inhibitor able to inhibit ammonia production [46], may also be valuable 
alternatives to fight H. pylori. 
Several studies have shown that phenolic compounds found in cranberries, green tea, 
apple and wine, affect H. pylori [55,56]. A recent study showed that both gallic acid and 
catechin, two abundant phenolic compounds widely distributed among plants [57], display 
growth inhibitory effects in H. pylori [47]. 
The encapsulation process appears as a solution for several problems associated with the 
administration of the drugs alone. These systems are able to protect the drug from rapid 
degradation or clearance, extending their half-life and solubility, and reducing its 
immunogenicity [33,58–60]. Previous studies [61] revealed that local application of antibiotics 
to gastric mucosa resulted in better eradication compared to systemically available 
antibiotic. Encapsulation allows not only local drug delivery but also a controlled release of 
the drug [62], thus increasing the retention and concentration at the site of infection [63,64]. 
In fact, previous studies have reported that the efficacy in eradicating H. pylori infection 
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may be  improved by delivering the antimicrobial agents from the gastric lumen into the 
mucus layer [31,32,65].  
Different strategies have been tested including floating drug delivery systems, density-
based approaches, mucoadhesive/bioadhesive systems and swelling systems for improving the 
gastric retention time of the system [5]. Several shapes and sizes can be acquired by these 
systems, including microspheres, nanoparticles, liposomes or other nano systems. 
Particularly, micro/nano particle systems made from naturally occurring biodegradable 
polymers have been developed and applied to H. pylori treatment [59,66], seeking to 
overcome the limits of the conventional application of drugs for H. pylori treatment, 
characterized by limited effectiveness, poor biodistribution and lack of selectivity. These 
have been preferred over the conventional dosage forms like tablet and capsule because of 
their increased surface area, which by  increasing the absorption of the drug reduces the 
dosing frequency, thus improving the patient compliance [5]. Moreover, because these 
tablets or capsules may fall to the base of the stomach from where they are readily emptied, 
little, if any, drug is delivered to the body or fundus of the stomach, being the main drug 
action through systemic effect [67]. 
In order to enhance the effect of the drug, further improvements on the micro/nano 
systems can be performed. Mucoadhesive polymers have been extensively used for gastric 
applications due to their ability to prolong the contact of the drug with the gastric mucosa 
[68], increasing residence time in the stomach [69] by adhering to the mucus layer [70]. 
Mucoadhesion is thought to occur due to electrostatic forces between the mucosal surface 
that is negatively charged and a positively charged polymer, followed by mechanical 
interlocking of the polymer chains, van der Waal’s force, hydrogen bonding and other forces 
[71,72]. This adherence allow micro/nano systems to more easily penetrate the gastric mucus 
barrier, which permit drug diffusion to occur without acidic degradation and at the desired 
local [5,30], therefore enhancing bioavailability and stability of the drug. Controlled release 
of a drug  may lead to lower administration frequency [69], thus minimizing the resistance 
problems associated with systemic administration of antibiotics [73]. 
Mucoadhesive polymer should fulfil some requirements such as strong hydrogen bond–
forming group, such as carboxylate or hydroxyl, strong anionic charge, high molecular weight, 
adequate chain flexibility, surface energy property favouring spreading onto the mucus and 
low or no toxicity [60]. Several materials have been considered for preparing these systems, 
including synthetic polymers, such as polylactic acid, copolymers of lactic, glycolic acids, 
poly(vinyl alcohol), and natural polymers such as chitosan [74]. 
1.6 Chitosan 
Chitosan (Figure 3), a naturally occurring polysaccharide composed of D-glucosamine and 
N-acetyl-D-glucosamine [75], is obtained by alkaline deacetylation of chitin, which is the 
second most abundant polysaccharide after cellulose [76,77]. Chitin is the principal 
component of the exoskeleton of crustaceans such as shrimps, crabs, prawns and lobsters, 
cell walls of some fungi such as aspergillus and mucor and insects [78]. The conditions used 
for deacetylation determines the polymer molecular weight and the degree of deacetylation 
(DD), which will directly affect the chemical and biological properties of the polymer [79]. 
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Figure 3 - Chemical structure of chitosan [80]. 
 
Chitosan is a polycationic, nontoxic, biodegradable and biocompatible polymer, stable in 
neutral conditions due to the strong inter and intra-molecular hydrogen bonds that the amine 
and hydroxyl groups on glucosamine unit are able to form [81]. Chitosan is a versatile 
polymer: its structure can vary considerably in size (average molecular weight; Mw) and DD 
[82], being this diversity exponentially increased by the numerous chemical modifications 
that are possible to perform [82].  
Its cationic character, along with the presence of reactive functional groups, has 
demonstrated chitosan as a valuable component in the preparation of mucoadhesive 
formulations [71,83]. 
Chitosan mucoadhesive [79] and antimicrobial properties [84–86] are particularly 
relevant, namely regarding the treatment of H. pylori [74].  
The mucoadhesive properties of chitosan result from the protonation of D-glucosamine 
residues at low pH, which leads to strong electrostatic interactions established between 
these charged free amines and gastric mucins, negatively charged at the acidic stomach pH 
[71,87,88]. He et al., [83] evaluated and demonstrated the excellent mucoadhesive 
properties of chitosan solution and chitosan microspheres. Turbidimetric measurement 
revealed a strong interaction between chitosan in aqueous solution and mucin, while in vitro 
studies with chitosan microspheres demonstrated similar results. The interaction between 
mucin and chitosan microspheres was suggested to be dominated by electrostatic attraction, 
which can be related to the effective surface charge. Mucoadhesion of chitosan microspheres 
in rat small intestine was also evaluated, revealing that not only chitosan microspheres 
adhere to mucins, they also can be adsorbed onto mucosal tissue. Factors such as ionic 
strength, surface charge and pH were found to influence interaction of the microspheres with 
mucins [83]. 
Regarding the antibacterial activity of chitosan, it is the consequence of the electrostatic 
interactions between the same cationic amino groups and the anionic groups on the bacterial 
wall, which leads to the inhibition of bacterial proliferation [88]. 
This polymer has been widely used in the pharmaceutical field as well as a carrier for 
drug delivery and as biomedical material [89], being commercially available in different 
forms, such as films, fibers, beads, scaffolds and micro/ nano particles [75]. 
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1.7 Chitosan as encapsulation system 
Chitosan micro [66,90] and nano [91,92] particles have been used to provide controlled 
release of many drugs and to improve the bioavailability of degradable substances such as 
proteins or enhance the uptake of hydrophilic substances across the epithelial layers. 
 
 Chitosan micro/nanoparticles production methods 
The production method selected for chitosan particles preparation is a relevant factor 
influencing its final features. The selection of the microencapsulation technique is primarily 
determined by the solubility of the drug and the polymer in various solvents systems [93,94], 
as well as by the particle size requirement [95]. To date, various methods and approaches 
have been proposed for the preparation of chitosan particles, such as ionotropic gelation, 
coacervation technique, spray drying, or emulsification/solvent evaporation (Table 1). 
Nevertheless, combination between the different methods can occur, depending on the 
purpose of the study and on the requirements established [96].  
It is important to prepare uniform-sized particles, controlling the size for their 
application in drug delivery system. The reproducibility of microspheres between batches is 
relevant when selecting the production method since it might lead to poor repeatability of 
the release behaviour and efficacy of drug among doses [97]. 
 
Table 1 - Examples of methods for preparation of chitosan micro/nanoparticles [74]. 
Particles production method Particle Size Advantages (+)/Disadvantages (-) 
Ionic gelation 
Drop wise addition of chitosan solution (positively charged) 
under constant stirring into a polyanionic solution (negatively 
charged, generally TPP). 
Complexation between oppositely charged species results 
in chitosan to precipitate as spherical particles. 
 
Nanoparticles (nm) 
20-200 [38] 
550-900 [33] 
152-376 [40] 
Microspheres (µm) 
~170 [41] 
100-400 [42] 
+ Processing under mild conditions. 
+ Organic solvent free. 
+ Low toxicity impact of reagents. 
+ No changes in drug chemistry. 
 
- Difficult entrapment of high molecular 
weight drugs. 
- Poor stability in acidic conditions. 
Precipitation/Coacervation 
1. Addition of a solute (generally a salt) to chitosan 
solution, forming micro/nanoparticles due to a decrease in 
chitosan solubility. 
2. Chitosan solution might also be blown into an alkali 
solution using a compressed air nozzle to form coacervate 
droplets. 
Nanoparticles (nm) 
100-250 [43] 
Microspheres (µm) 
1.5-2.5 [44] 
+ No complex apparatus needed. 
+ Few purification steps required. 
+ Organic solvent free. 
+ High loading capacity combined with a 
sustained drug release. 
 
- Poor stability in acidic conditions 
Spray drying 
Preparation of chitosan solution where a suitable cross-
linking agent could be added (if desired). This solution or 
dispersion is then atomized in a stream of hot air. Atomization 
leads to the formation of small droplets, from which solvent 
evaporates instantly leading to the formation of free flowing 
particles. 
Temperature and humidity might be regulated. 
Microspheres (µm) 
3-12 [45] 
140-281 [46] 
 
+ Simple, reproducible, and easy to scale 
up. 
+ Low cost process. 
+ Fast solvent removal. 
+ Good sphericity. 
+ Narrow size distribution. 
+ Low dependency of the solubility of 
the drug and polymer. 
 
- High temperatures required. 
- Size influenced by several parameters. 
- Possible difficulty in spraying fluid of 
high viscosity. 
Supercritical anti-solvent precipitation 
Spraying of the chitosan solution into a precipitation 
chamber with supercritical CO2 (anti-solvent), causing rapid 
contact between the two media. A higher super-saturation 
ratio of the solution is generated, resulting in fast nucleation 
and growth. 
Microparticles (µm) 
1.0- 2.5 [47] 
 
+ Processing under mild conditions. 
+ Complete anti-solvent removal. 
+ Non-toxic reagents. 
+ Narrow size distribution. 
+ No changes in drug chemistry. 
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Emulsion cross-linking 
Chitosan aqueous solution is extruded into an oil phase, 
generally liquid paraffin (under intensive stirring), forming and 
water-in-oil (w/o) emulsion. Aqueous droplets are stabilized 
by adding a surfactant. The stable emulsion is cross-linked by 
using an appropriate cross-linking agent such as 
glutaraldehyde. 
Microspheres (µm) 
60-100 [48] 
100-330 [49] 
350-690 [50] 
+ Control of particle size. 
+ Good sphericity. 
 
- Slow process. 
- Chemical cross-linking agents used, 
possibly inducing chemical reactions 
with the drug. 
- Difficult removal of the unreacted 
cross-linking agent. 
Solvent Evaporation 
Aqueous chitosan solution is added to an organic phase 
with vigorous stirring to form the primary water in oil 
emulsion (w/o). The latter is then added to a large volume of 
water containing a surfactant, forming a multiple emulsion 
(w/o/w). The double emulsion is then subjected to stirring 
until most of the organic solvent evaporates, leaving solid 
microspheres. 
Microspheres (µm) 
100-200 [51] 
+ Processing under mild conditions. 
+ Favorable for encapsulation of 
thermally sensitive drugs. 
+ Indicated for delivery of small 
molecule drugs. 
+ Good sphericity. 
 
- Organic solvents usage. 
- Low drug encapsulation efficiency. 
 
Reverse micellar method 
The surfactant is dissolved in an organic solvent followed 
by the addition of chitosan, drug and cross-linking agent, 
under constant vortexing overnight. The organic solvent is 
evaporated, obtaining a transparent dry mass. The latter is 
dispersed in water and then a suitable salt is added to 
precipitate the surfactant out. 
Nanoparticles (nm) 
~100 [52] 
+ Narrow size distribution. 
 
- Organic solvent usage. 
 
Due to the high solubility of chitosan in the gastric fluids [75,98], it is important to 
consider mechanisms able to enhance its mechanical and physical properties during the 
micro/nano particles production, so that a gastric application, such as for the treatment of 
H. pylori, is viable. When associated to drug delivery, the dissolution of the chitosan can be 
restrictive, since due to the protonation of the glucosamine residues of the chitosan in the 
acidic pH, an extensive swelling of the microsphere is verified, followed by a faster release of 
the drug [31], which might not be desirable. As a consequence, low retention time and 
difficulty in crossing the mucus barrier have been observed as well [43].  
 
 Chitosan micro/nanoparticles stability under acidic conditions: crosslinking  
In order to overcome this restriction and to preserve the stability and three dimensional 
structure of chitosan gel under gastric conditions or enzymatic degradation, physical and 
chemical modifications of chitosan have been used as a reinforcement strategy of the 
chitosan structure, improving its mechanical resistance and chemical stability in acidic 
solutions [75,81,95,98].  
Tripolyphosphate (TPP), a non-toxic polyanion able to interact with chitosan via 
electrostatic forces, is conventionally used to form ionic crosslinked networks [98]. However, 
although TPP has fast gelling ability and higher stability in acid than the chitosan alone [98], 
it is difficult to accurately control the physical gel pore size, chemical functionalization, 
dissolution and degradation [79]. As an alternative, chemical crosslinking agents, mainly 
glutaraldehyde, have been considered [99,100]. Glutaraldehyde reacts with chitosan forming 
covalent bonds mainly with the amino groups of the polymer. However, glutaraldehyde, as 
well as other synthetic crosslinking reagents, is cytotoxic, which may impair the 
biocompatibility and biodegradability of the microspheres [101,102]. Biocompatible natural 
occurring crosslinking agents have therefore been thoroughly investigated, seeking for a less 
cytotoxic agent, able to form stable and biocompatible crosslinked products. Genipin is 
particularly effective for chemically crosslink polymers containing amino groups [79], forming 
secondary amides and heterocyclic amino linkages [101]. Sung et al. [103] have found that 
genipin-crosslinked networks are significantly less cytotoxic (about 5000–10000 times) than 
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those crosslinked by glutaraldehyde [100,104], and also that they degrade slower than 
glutaraldehyde-crosslinked ones [105].  
Conjugation of crosslinking methods [32] is also a valuable possibility in order to improve 
its usage for biomedical applications. Mi et al. [81] produced chitosan gel beads by the 
fixation of its amine groups with a co-crosslinking agent composed of TPP (ionic crosslinker) 
and genipin (chemical crosslinker). Simply, the negative charged TPP ions react with positive 
charged chitosan through electrostatic interactions, while genipin reacts with chitosan via 
covalent bonding [75,98]. However, this interaction was found to be dependent on the pH 
value of the co-crosslinker [81,106]. UV (Ultra Violet Spectroscopy), FTIR (Fourier Transform 
Infrared Spectroscopy) and EDAX (X- ray energy dispersion) analysis revealed that chemical 
crosslinking by genipin can be inhibited due to the presence of H+ in the co-crosslinking 
process, significantly encouraging the ionic crosslinking reaction while diminishing the 
chemical crosslinking reaction. Depending on the pH, chitosan can bind more easily with TPP 
ions (low pH) or with genipin (neutral or alkaline pH), fact related to the presence 
of   ,      
  ,    and     on the solution. Different pH conditions will alter the 
concentration of these ions and therefore crosslinkers relation with chitosan: ionic 
crosslinking will be the dominant reaction at lower pH, while  the chemical crosslinking of 
chitosan with genipin will dominate the reaction of co-crosslinking at higher pH [81]. Shah et 
al., [32] developed drug containing microspheres prepared by ionic crosslinking (TPP) and 
precipitation. Chitosan microspheres were loaded with amoxicillin and metronidazole, 
capable of adhere to the mucus layer, releasing the contents locally at the site of infection.  
Apart from crosslinking, alternative approaches can be considered, such as reacetylation 
for instance with acetic anhydride, strategy that has been shown to reduce chitosan solubility 
and improve drug release capacity of the microspheres [107].   
 
 Influence of crosslinking degree on chitosan particles properties 
Nevertheless, chitosan modifications should be addressed carefully, since chitosan final 
properties depend on the extent of crosslinking reaction [95,108]. Its swelling ability, and 
consequently the release rate of the drug, as well as its mucoadhesive properties might be 
affected [101,109]. As previously said, the latter may be attributed to molecular attractive 
forces formed by electrostatic interaction between positively charged chitosan and negatively 
charged mucosal surfaces [106], and therefore by increasing the degree of crosslinking, the 
number of free primary amines will be reduced. Consequently, the possible ligand density 
and the polymer reactivity may also decrease as well as the accessibility to internal sites of 
the material, leading to a loss in the flexibility of the polymer chains [95]. Apart from 
crosslinking, ionic modification and salt formation can also affect the mucoadhesive 
properties of chitosan [110,111]. 
 
In order to control the crosslinking degree, several factors must be taken into account 
(Table 2), including not only concentration and volume of crosslinking agent, incubation time, 
temperature and stirring speed, but also MW and DD of chitosan [90,95]. When designing a 
particle for a specific application, all these factors should be taken into account during 
preparation [112], so that an optimized system can be developed.  
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Table 2 – Factors influencing chitosan micro/nano particles features.  
Chitosan Size Charge Swelling 
Molecular weight 
 [113]  
Degree of deacetylation (%) 
[114] [113]  
Concentration (%w/v) [115]  [115] 
Polymer-drug ratio [90] [90] [90] 
Crosslinking [83,90] [83,90] [75,109] 
  
Regarding crosslinking, by increasing agent or volume of crosslinker, incubation time or 
temperature, crosslinking degree is increased. A high degree of deacetylation of chitosan 
favours crosslinking since it requires mainly deacetylated reactive units. The size of the 
particle is strongly dependent on the concentration of the solutions [33], and the higher the 
degree of crosslinking, the less irregular are the microspheres, and the smaller the particle 
size [83], due to the shrinking of the network observed. The charge of the particle, and 
therefore its mucoadhesive properties, is evaluated through potential zeta, and is reduced 
when the crosslinker volume, incubation time or stirring speed is increased [83,90]. The 
swelling ability influences the drug release profile, which is normally decreased when the 
incubation time and therefore the degree of crosslinking is increased  [75,109]. Prolonged in 
vitro drug release time is also associated with higher degrees of crosslinking [115]. 
All these parameters represent consequences regarding particles performance in vitro 
and in vivo, and therefore should be evaluated carefully. For instance, because the 
accumulated locations of the microspheres containing drug depend on the size of the 
particles, if the size distribution of microspheres is broad, the bioavailability of drug will be 
low and the side-effects of the drug will be increased [97].  
1.8 Chitosan as a binding agent 
Despite the growing application of chitosan particles as drug delivery vehicles, low 
retention of microspheres in the stomach, resistance to the delivered antibiotics, amongst 
other factors have prevented the development of efficient therapies against H. pylori, 
therefore persisting the need of alternative options for the treatment of H. pylori infection 
[74]. 
The antimicrobial activity of chitosan and its derivatives was observed against several 
bacteria [116,117], fungi [118] and parasites [119]. In liquid medium, chitosan was able to 
inhibit the growth of some spoilage bacteria such as Bacillus subtilis IFO 3025, Escherichia 
coli RB, Pseudomonas fragi IFO 3458 and Staphylococcus aureus IAM 1011 [120].  
Antimicrobial activity of chitosan or chitosan-based films has also been investigated, 
showing reduced microbial growth [117,121,122]. Leceta et al., [123] evaluated the 
antimicrobial activity of chitosan-based films and chitosan ﬁlm forming solutions against E. 
coli 0517H, and L. plantarum CECT748, observing that only chitosan ﬁlm forming solutions 
presented antibacterial properties, whereas chitosan-based ﬁlms dried at room temperature 
only showed bacteriostatic properties. Particularly, chitosan ability to bind and kill H. pylori  
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has been investigated and demonstrated [124], revealing new potential therapies against H. 
pylori. 
Nogueira et al. [124]  produced chitosan thin films and evaluated its effect on H. pylori in 
a pH range that simulates gastric conditions (2.6, 4.0 and 6.0). Results revealed that chitosan 
films were able to induce cell death of more than 75% of the adherent bacteria, 
independently of pH. Therefore, the potential use of chitosan-based biomaterials as 
adjuvants in the elimination of H. pylori gastric infection might be a valuable option.  
In fact, Fernandes et al. and Gonçalves et al. [43,108] produced chitosan microspheres 
that rather than being used as a vehicle for gastric drug delivery, were designed and applied 
as an H. pylori-binder system. The rational of the strategy consists on eliminating H. pylori 
present in the stomach by binding the bacteria and impairing its adhesion to host cells. As 
binding agent, it is important to prevent dissolution of microspheres while maintaining its 
mucoadhesive properties, so that binding can happen, followed by removal of the bacteria 
intact from the stomach, through the intestinal tract, after gastric mucosal turnover. 
Furthermore, the microsphere should have a size which allows it to effectively bind H. pylori 
bacteria. Bacteria contained in the stomach but not adhered to the gastric mucosa or mucus 
layer can also be bound by the microspheres [43]. Therefore, a diameter between about 70 
m and about 200m would allow the microspheres not only to adhere to bacteria present on 
the mucus barrier, but also to bacteria adhered to foveolaes.  
This system was further improved by directing the microspheres toward H. pylori. 
Glycosilated receptors that specifically bind to molecules displayed on the surface of H. 
pylori bacteria were incorporated on the system [125], thereby adsorbing the bacteria so that 
they can be removed from the gastric mucosa and/or mucus layer or prevented from binding 
to the gastric mucosa and/or mucus layer. The glycan receptors of H. pylori include 
fucosylated blood group antigens, such as Lewis B and/or Sialyl-Lewis X receptors. By 
removing bacteria from the stomach, colonisation of the gastric mucosa and mucus layer by 
H. pylori bacteria is reduced, and re-colonisation can be reduced or prevented.  
1.9 Active targeting to improve H. pylori treatment 
Active targeting can provide the system specificity by directing it towards the mucosal 
surfaces or bacteria. Complex systems can combine bioadhesive properties, selective targets 
and delivery of the drugs, resulting in a system with improved ability to effectively kill and 
eradicate H. pylori. Any ligand/drug with a high binding affinity for mucins or for the 
bacteria can be covalently linked to the microspheres with the appropriate chemistry [5,59]. 
Depending on the purpose, lectins, bacterial adhesins, amino acid sequences or antibodies 
can be used, either to increase adhesion of bioadhesive microspheres to specific cell surface 
glycoproteins, mucins or bacteria wall [126]. 
Particularly, lectin-conjugated nanoparticle systems, which may bind to the carbohydrate 
residue present on the bacterial surface, have been proposed and play an effective tool for 
eradication of H. pylori. This may influence its adherence to the membrane of surface 
mucous cells [127].  
A study performed by Ramteke et al. [33] demonstrated the efficacy of a more complex 
system on the delivery of antibiotics: chitosan-glutamic acid nanoparticles containing triple 
therapy were produced by ionotropic gelation. With a particle size ranging between 550nm 
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and 900nm, the nanoparticles showed to inhibit growth of H. pylori, however the drug was 
totally released within the first 5h. In order to improve the selectivity and efficacy of the 
nanoparticles, the authors functionalized the chitosan nanoparticles with α(L)-fucose, 
verifying an improvement on the antibacterial effect when comparing to non-conjugated 
ones. The fucose-conjugated formulations showed strong agglutination with H. pylori, 
confirming the presence of lectin type receptors on the surface of H. pylori that can 
selectively bind with the specific ligand present on nanoparticles. In vitro antibacterial 
studies revealed a higher eradication rate for monotherapy when functionalized nanoparticles 
were used when comparing to non-functionalized. Triple therapy showed once again to have 
better effects when applied with functionalized nanoparticles, with an eradication rate of 
97.17% against 91.01% for non-conjugated chitosan nanoparticles and  81.32% for plain triple 
therapy. These results show superior targeting potency toward lectin receptors on H. pylori 
surface. Chitosan nanoparticles without antibiotics, both functionalized and non-
functionalized, were shown to possess antimicrobial activity against H. pylori, with a 
maximum % of growth inhibition of 5.13% for non-functionalized nanoparticles and 7.9% for 
functionalized ones. In vivo tests demonstrated the H. pylori elimination from the stomach of 
the mice after administration of the nanoparticles. An eradication of 100% was found for 
functionalized nanoparticles, confirmed by the negative results of the Gram-staining and 
urease test. Non-functionalized ones presented an eradication rate of 50% or less, while plain 
triple therapy presented even lower values.  
To notice that functionalization leads to an increase in the particle size [33], which 
depending on the application, may not be desired. 
  
 
 
 
Chapter 2  
Aim 
The overall aim of this project lies on the production and study of the ability of 50 µm H. 
pylori-binding chitosan microspheres to penetrate the gastric foveolae, using for that ex-vivo 
models consisting of mice and human fresh stomachs. 
 
So that the global aim could be achieved, the work was subdivided into three major 
sections: 
 
1. Production of chitosan microspheres 
 
Previous studies have demonstrated the ability of chitosan microspheres to interact with 
H. pylori and adhere to the gastric mucosa. However, previously developed chitosan 
microspheres presented a diameter around 170 µm, which hampered the penetration and 
removal of the bacteria installed inside the foveolae. For that reason, the development of 
smaller microspheres is crucial to reach the bacteria adhered to the surface of gastric 
epithelial cells. Previous studies using 2D sections of human gastric mucosae have shown that 
human stomach foveolae are ~70 µm wide, therefore microspheres with approximate size of 
50 µm should ideally be used.  
For this purpose, chitosan microspheres were produced by ionotropic gelation, though 
recurring to three different equipments, namely high voltage electrostatic system, co-axial 
air stream system and aerodynamically driven system.  
 An intensive screening of several parameters was performed before selecting the best 
condition. Chitosan degree of acetylation (DA) was one of the parameters assessed and its 
effect was evaluated on the production process. From two DA (6% and 16%), differing in the 
number of primary amines available to establish other reactions, the lowest one was selected 
in order to potentiate the mucoadhesive properties of the microspheres.  
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In order to be stable in the gastric acidic conditions, chitosan microspheres will be 
crosslinked with genipin. Both genipin crosslinking and chitosan mucoadhesive properties are 
processes dependent on the amount of active primary amino groups present on the chitosan 
D-glucosamine units. Therefore, the crosslinking process must be controlled and readjusted 
to the selected microspheres. Morphology and size distribution of chitosan microspheres were 
analysed by three different equipments, based on optical microscopy coupled with image 
acquisition (Optical Microscopy and IN Cell Analyzer high-throughput microscopy) and laser 
diffraction (Mastersizer equipment). 
 
2. Penetration of chitosan microspheres into the gastric mucosa 
 
Following the production of the aimed chitosan microspheres with size average around 50 
µm, the evaluation of their ability to penetrate the gastric foveolae is crucial to accomplish 
to remove H. pylori present within the gastric foveolae. An ex-vivo model was chosen since it 
allows mimicking the 3D structure of the stomach while preserving its mucus layer, which is 
enrolled on bacteria adhesion process. 
 Since mice have been frequently used as an animal model to study H. pylori infection, 
preliminary studies regarding labelling optimization were performed using fresh stomachs 
from C57BL/6 mice strain. Nucleic acids and plasma membrane stains were tried out in fixed 
and fresh stomachs. 
Adhesion studies relied on the incubation of the fresh stomach with the chitosan 
microspheres at 37ºC, for a 2h-period, at pH 6.0, followed by the specific labelling. Samples 
were observed under fluorescence and confocal laser scanning microscopy. Citrate-phosphate 
buffer was used at pH 6.0 since it allows mimicking the acidic stomach conditions, 
particularly the ones near the epithelial cells (pH 6.0). 
 
3. Evaluation of the adhesion of chitosan microspheres to H. pylori 
 
The ability of the chitosan microspheres to interact with H. pylori is also relevant to the 
whole process. Therefore, J99 H. pylori strain, obtained from human isolates and presenting 
BabA and SabA adhesins on its surface, was selected to conduct the adhesion studies.  
The chitosan microspheres prepared were incubated with H. pylori for 2h-period. In order 
to evaluate if being alive would influence the in vitro interaction of H. pylori with chitosan 
microspheres, parallel studies were conducted using FITC-fixed J99 strain and live bacteria, 
using nucleic acid stains. Fluorescence microscopy was used to visualize the samples as well 
as confocal laser scanning microscopy, the latter to better assess bacteria adhesion and to 
evaluate whether bacteria only adheres to the surface of the microsphere or if it goes inside. 
 
 
  
 
 
 
Chapter 3 
Materials and Methods 
3.1 Chitosan Microspheres Preparation 
3.1.1  Chitosan purification 
Squid pen chitosan powder with a DA of 6% (MW> 500,000 Da) and 16% (MW 283,000-
472,000 Da) was weighted, separately, and dried for 24 h inside a vacuum oven (60ºC). 
Afterwards, chitosan was hydrated in Milli-Q water for 24 h at 4ºC and glacial acetic acid was 
added to achieve a final concentration of 0.2 M, being kept overnight at room temperature. 
Chitosan should be protected from light all the time as it is sensitive to it. Chitosan solution 
was then filtered and precipitated by addition of NaOH, until the solution was alkaline. 
Chitosan suspension was centrifuged, the supernatant was discarded and deionized water was 
added, followed by pellet resuspension. This process was repeated 3 times. Chitosan 
suspension was then frozen at -80ºC, and lyophilised for 72 h. Lastly, chitosan was milled 
until a fine powder was obtained. 
3.1.2  Preparation of chitosan solution  
Purified chitosan powder was dried in a vacuum oven at 60°C for 24 h. Chitosan was 
previously hydrated using Milli-Q water at 4°C under slow magnetic stirring, and after 24h 
incubation, glacial acetic acid was added to achieve a final concentration of 0.1 M and left 
overnight under moderate stirring at room temperature. For each DA, three solutions with 
different concentrations of 0.5%, 1% and 1.5% (w/v) were prepared. Afterwards, each 
chitosan solution in acetic acid was filtered using a 5 µm pore size syringe filter (Millipore) 
followed by a 0.8 µm pore size filter (Millipore). 
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3.2 Chitosan microspheres production 
Chitosan microspheres were produced by ionotropic gelation into a sodium triphosphate 
pentabasic (TPP; Sigma-Aldrich) solution (pH 9.0) using three different methods. The aim was 
to identify the system able to provide the most suitable microspheres, with adequate size 
and morphology. Several parameters were varied in order to optimize the microspheres 
production.   
3.2.1  High voltage electrostatic system 
Chitosan microspheres were produced in a high voltage electrostatic system (Nisco 
Encapsulation UnitVar 1, NISCO). Briefly, a syringe with chitosan solution was placed on a 
syringe pump and connected to the nozzle. A voltage of 7.0 kV/cm was applied between the 
needle feeding the chitosan solution and the 5% (w/v) TPP solution underneath. This voltage 
forces the droplets to fall off the 0.09 mm diameter needle tip (PE-00515, Nisco) into the TPP 
eletroconductive solution. The chitosan solution flow rate was adjusted and TPP solution was 
subjected to slow stirring (35 rpm). Conditions evaluated are specified in Table 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                          
Figure 4 - High voltage electrostatic system. 
3.2.2  Co-axial air stream system 
Chitosan microspheres were produced by droplet extrusion under co-axial air stream 
(Nisco Encapsulation Coaxial Airflow Induced Dripping VAR J1, NISCO). Briefly, a syringe with 
chitosan solution was placed on a syringe pump and connected to the nozzle. The unit is 
equipped with two connections, one for the hose which provides the chitosan solution, and 
the other connection being aimed for an air hose. Chitosan droplets were extruded through a 
needle (PE-00515, Nisco) into a 5% (w/v) TPP solution, under a co-axial air stream with 
controlled pressure, which blows the chitosan droplets from the needle tip into the TPP 
gelling bath before they would fall due to gravity. Syringe pump flow rate was adjusted and 
the microspheres were formed under slow stirring (35 rpm). A number of parameters were 
Chitosan solution 
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investigated by changing one parameter while keeping the others constant. Conditions 
evaluated are specified in Table 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 5 - Droplet extrusion under co-axial air stream system. 
3.2.3  Aerodynamically driven system 
Chitosan microspheres were produced by an aerodynamically driven system (Nisco 
Encapsulation Unit Var J30, NISCO). Briefly, the syringe with the chitosan solution is placed 
on the syringe pump and connected to the nozzle. The chitosan enters through a central 
needle, which is enclosed in a pressure chamber with an exit through the oriﬁce. A second 
orifice allows air to enter the chamber, which pressure can be ﬁxed with a potentiometer. 
The exit orifice, which is centrally in line with the axis of the needle, has been counter-sunk 
externally. The counter sunk leads to the aero dynamical effect so that the jet has a smaller 
diameter when passing the orifice than before at the needle. Since the size of the drops is 
determined by the chitosan flow rate and the pressure inside the chamber, these parameters 
were investigated, as well as chitosan solution concentration. Only degree of acetylation of 
6% was used in this method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – Aerodynamically driven system. 
Chitosan solution 
Air 
Chitosan solution 
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3.2.4  Variable conditions 
Table 3 shows the parameters varied during microspheres production, regarding the three 
methods tested. 
 
Table 3 – Conditions tested during Ch microspheres production. 
 
Ch degree of 
acetylation 
Ch solution 
concentration 
Syringe pump 
flow rate 
Air stream 
pressure 
Nozzle 
diameter 
High voltage 
electrostatic 
system 
6% 
16% 
0.5 % (w/v) 
1 % (w/v) 
1.5 % (w/v) 
0.4 mL/h 
1 mL/h 
10 mL/h 
20 mL/h 
NA NA 
Droplet extrusion 
under co-axial air 
stream system 
6% 
16% 
0.5 % (w/v) 
1 % (w/v) 
1.5 % (w/v) 
0.4 mL/h 
1 mL/h 
10 mL/h 
20 mL/h 
0.25 bar 
0.4 bar 
0.6 bar 
1 bar 
NA 
Aerodynamically 
driven system 
6% 
0.5 % (w/v) 
1 % (w/v) 
0.25 mL/min 
0.33 mL/min 
0.5 mL/min 
1 mL/min 
0.205 bar 
0.525 bar 
0.25 mm 
0.50 mm 
NA – not applicable 
 
3.3 Chitosan microspheres characterization 
3.3.1  Size and morphology 
Chitosan microspheres were characterized mainly regarding size and morphology by 
different techniques, each one providing complementary information. Three equipments 
were used to perform the analysis of the particles. 
3.3.2  Optical Microscopy 
Optical microscopy was first used to roughly determine the average diameter of the 
chitosan microspheres. The latter were transferred to 24-well plates and images were 
acquired in Bright field using the 10x objective. Diameter of manually selected chitosan 
microspheres was then measured using AxioVision Software (Zeiss), always horizontally in the 
larger part of the microspheres to avoid bias. 
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3.3.3  IN Cell Analyzer 
IN Cell Analyzer 2000 (GE Healthcare) is a super-fast, sensitive, and flexible wide-field 
cell imaging system, which simultaneously allows the acquisition of high quality images and 
posteriorly the analysis of morphological parameters.  
Chitosan microspheres were transferred preferentially to a 96-well plate, and an 
automated screening was performed throughout all the specified wells. Images were acquired 
in 10x objective using Bright field. Afterwards, in the coupled IN Cell Developer Toolbox, a 
customized protocol was created for chitosan microspheres quantification and analysis. 
Initially, the target to be located and measured, that is each microsphere, was defined. After 
that, pre-processing operations were implemented in order to make the microspheres easy to 
detect, namely operations that erode and dilate image features, reduce noise and correct 
uneven background intensity. To separate and isolate the microspheres from the remaining 
image features, a segmentation algorithm was implemented based on particular sizes, shapes 
and intensities. After defining what is considered a microsphere, specific measurements were 
selected from a library of pre-defined morphological and densitometric measures: area, 
length, average diameter, maximum chord and form factor of each microsphere were 
determined. This protocol was then applied to each image acquired, providing a list of the 
selected measures for each microsphere identified by the protocol. The associated software 
Spotfire™ DecisionSite™ allowed an interactive visualization of the obtained data through 
different graphs. From these graphs, outsiders were eliminated as well as particles smaller 
than 10 µm, which in most of the cases were debris and artefacts of the image. Only after 
this analysis, average measures regarding microspheres characteristics were considered.  
3.3.4  Mastersizer 
Mastersizer 3000 (Malvern) is a particle sizing instrument which uses the technique of 
laser diffraction to measure particle size distributions, from 0.01 µm up to 3.5 mm.  
Chitosan particles are drawn into a water container (The Hydro EV, Malvern) until enough 
sample is recognized. Five measurements are performed for each sample and a sequential 
combination of measurements with red and blue light sources is used to measure across the 
entire particle size range. Sonication can be applied to increase separation between chitosan 
particles. The coupled software gives the information regarding microspheres size. Given that 
it cannot be assured that all the microspheres are exactly spheres, the particle size is defined 
using the concept of equivalent spheres. In this case, the microspheres size is reported as a 
volume equivalent sphere diameter, meaning that the particle size is defined by the diameter 
of an equivalent sphere having the same volume. A volume weighted distribution is then 
given where the contribution of each particle in the distribution relates to the volume of that 
particle. Apart from the histogram regarding the size distribution, parameters based upon the 
maximum microspheres size for a given percentage volume of the sample, named percentiles, 
are reported. Percentiles Dv10, Dv50 and Dv90 are given, being D diameter, v volume 
(specifying the distribution weighting) and 10, 50 and 90 the percentage of sample below this 
particle size. 
 
Since microspheres produced in aerodynamically driven system VarJ30 under 525 mBar 
pressure, 0.5 mL/min flow rate with 0.25 mm nozzle and chitosan with DA 6% at 0.5% (w/v) 
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presented the average diameter of 50 µm aimed, they were selected for all subsequent 
studies.  
3.4  Genipin crosslinking kinetics 
Chitosan microspheres were rinsed three times with Milli-Q water by centrifugation at 10 
000 rpm for 7 min. After that, in order to determine the adequate crosslinking level of 
chitosan microspheres, the crosslinking kinetics was assessed at various time points. Briefly, 
20 µL of rinsed chitosan microspheres suspension were transferred to a 24-well plate and 500 
µL of 10 mM genipin (Wako Chemicals GmbH) solution prepared in 0.01 M phosphate buffer 
saline (PBS) (Sigma, pH 7.4) were added. The crosslinking level of chitosan microspheres was 
determined using an Inverted Fluorescence Microscope (IFM, AxioVert, Zeiss). Images were 
taken every 15 min over a 12-h period. Single chitosan microspheres were visualized in the 
DAPI channel (470 nm) and their densitometric mean fluorescence was followed over time.  
From the kinetics study a time point corresponding to an intermediate crosslinking degree 
was selected and chitosan microspheres were incubated in 10 mM of genipin solution over 45 
min under 120 rpm stirring at 25ºC. After crosslinking, the microspheres were rinsed three 
times by centrifugation with Milli-Q water, frozen in liquid nitrogen and lyophilised at -80ºC 
for 96 h.  
3.4.1  Stability in acidic conditions 
The acidic stomach conditions in the mucus layer near the epithelial cells were mimicked 
by phosphate-citrate buffer (citric acid 0.1 M and Na2HPO4.2H2O 0.2 M) at pH 6.0. Briefly, 20 
µL of crosslinked chitosan microspheres were transferred to a 24-well plate and 500 µL of 
phosphate-citrate buffer were added. Chitosan microspheres were visualized by OM and 
images were taken every 5 min over an hour. 
 
3.5 Chitosan microspheres adhesion to gastric mucosa 
 The efficiency of chitosan microspheres to adhere and penetrate the gastric mucosa was 
evaluated using stomach fresh samples. The model was first optimized using mice gastric 
mucosa, followed by further assessment using human gastric samples. Incubations were 
performed in phosphate-citrate buffer pH 6.0 at 37°C under 70 rpm. 
Figure 7 - Crosslinking reaction mechanism between chitosan and genipin [108]. 
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3.5.1  Gastric mucosa labelling optimization 
Gastric mucosa labelling optimization was performed using mice stomachs.  
Stomachs from 6 to 10 week old wt C57BL/6 mice strain were obtained from Animal 
House at IBMC/INEB (Porto, Portugal) and used shortly after its sacrifice using carbon dioxide 
inhalation. Stomachs were opened through the great curvature from the duodenum to 
oesophagus using chirurgical scissors, obtaining a butterfly-like shape. The food contents 
were gently removed using 0.01 M PBS (pH 7.4) in order to preserve the stomach mucus layer. 
Then, a cut through the mice stomach smaller curvature was done in order to divide this 
organ in two halves. Each half was used separately corresponding to an individual stomach 
sample. 
 
To better assess the penetration of chitosan microspheres, gastric mucosa was labelled 
recurring to nuclear and plasma membrane stains. 
 
 
Table 4 – Nuclear and plasma membrane stains evaluated. 
 
Stains 
Fluorescence 
excitation (nm) 
Fluorescence 
emission (nm) 
Concentration 
(µg/mL) 
Incubation 
time (min) 
N
u
c
le
a
r 
 
DAPI 350 470 
1 (1:100) 
10 (1:100) 
15 
Hoechst 350 461 
1 (1:100) 
10 (1:100) 
15 
P
la
sm
a
 m
e
m
b
ra
n
e
 
Wheat Germ 
Agglutinin (WGA), 
Alexa Fluor® 350 
conjugate 
346 442 5 15 
WGA, Alexa Fluor® 
488 conjugate 
495 519 1 
15 
30 
WGA, Alexa Fluor® 
594 conjugate 
590 617 
5 
20 
15 
WGA, fluorescein 
conjugate 
494 518 5 15 
CellMask™ Deep Red 649 666 1000X - 
 
Regarding the nucleic acid stains, since DAPI is recommended for fixed or permeabilized 
cells, some samples were initially fixed with paraformaldehyde (PFA) 4% before staining.  
Moreover, both DAPI and Hoechst were mounted using two different mounting media, namely 
Vectashield and Fluoromount. 
Samples concerning the plasma membrane staining, Wheat Germ Agglutinin conjugates 
(WGA, Invitrogen) and CellMask™ Deep Red (Molecular Probes), were kept fresh, and no 
fixation or mounting process was performed.  
Samples were observed with IFM and a Leica SP2 and SP5 confocal laser scanning 
microscope (CLSM, Leica Microsystems).  
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3.5.2  Chitosan microspheres adhesion to mice gastric mucosa 
Chitosan microspheres were firstly sonicated for 8 min, followed centrifugation (10000 
rpm, 7 min) in order to transfer the microspheres (kept in ethanol 70%) to the pH 6.0 buffer. 
Afterwards, microspheres were counted using IN Cell Analyzer high-throughput microscopy 
and 500 microspheres in 60 µL of phosphate-citrate buffer pH 6.0 per sample were added to 
mice gastric mucosa for 2 h in 6-well plate covered with parafilm. Afterwards, samples were 
rinsed three times in 1 mL of 0.01 M PBS and mucosa labelling was performed. After that, 
samples were once again rinsed in 0.01 M PBS and visualized by IFM and CLSM.  
3.5.3  Chitosan microspheres adhesion to human gastric mucosa 
Human gastric mucosae were provided by Hospital São João (Porto, Portugal) and were 
obtained from stomach portions that were removed after a partial gastrectomy.  
Chitosan microspheres adhesion to the mucosa was done similarly to the adhesion assay 
using mice gastric mucosa. CellMask™ Deep Red was used as stain. 
3.6 Helicobacter pylori adhesion to chitosan microspheres 
Apart from being able to penetrate gastric mucosa, chitosan microspheres must have the 
capability of adhering to Helicobacter pylori (H. pylori), so that they can afterwards remove 
the bacteria from the gastric foveolae.  
Since the in vivo adhesion of H. pylori to chitosan microspheres occurs with the bacteria 
alive, two independently adhesion assays were conducted with live and previously fixed J99 
H. pylori strain, in order to understand whether the adhesion of H. pylori to chitosan 
microspheres might be influenced by the bacteria being alive. 
3.6.1  H. pylori strain and culture conditions 
H. pylori strain J99, obtained from human isolates, was obtained from the Department of 
Medical Biochemistry and Biophysics, Umeå University, Sweden [128]. Bacteria were cultured 
in OXOID Blood Agar base 2 (Probiológica) supplemented with 10% defibrinated horse blood 
(Probiológica) and antibiotic/antifungal cocktail at 37°C, for 48 h, under microaerobic 
conditions. Bacteria were then spread and incubated for another 48 h. At the end of the 
incubation period, bacteria were harvested using 0.01 M PBS and their optical density at 600 
nm (OD
600
) was measured. Bacteria inoculum was adjusted to an optical density (OD
600
) of 
0.08 using pH 6.0 phosphate-citrate buffer.  
H. pylori previously fixed and labelled with fluorescein isothiocyanate (FITC) and frozen 
according to the protocol described in [129] was also used (OD
600
1.0).
 
3.6.2  Adhesion of H. pylori J99 strain to chitosan microspheres  
Chitosan microspheres were incubated with live or FITC- labelled H. pylori at a final 
optical density (OD600) of 0.04, corresponding to 1 × 10
7
 colony forming units (CFU) per mL, 
for 2 h, under 120 rpm stirring with a final incubation volume of 60 µL of phosphate-citrate 
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buffer at pH 6.0. Adhesion assay with live bacteria was conducted at 37ºC while the assay 
with FITC-labelled bacteria was carried out at room temperature (RT). After incubation, in 
order to remove non-adherent bacteria, microspheres were rinsed five times using 500 µL of 
0.01 M PBS by centrifugation at 10 000 rpm, for 7 min.  
Regarding live bacteria assay, staining was performed after the adhesion, with DAPI (10 
µg/mL) and Hoechst (10 µg/mL) as nucleic acid stains.  
Microspheres were gently transferred to microscope slides. A drop of fluorescence 
mounting medium (Vectashield and Vectashield with DAPI) was added, a glass coverslip was 
placed on top of the preparation and observed under IFM and CLSM. 
 
 
 
 
 
 
 
 
 
  
 
 
 
Chapter 4 
Results and Discussion 
4.1 Chitosan microspheres production and characterization 
Chitosan microspheres were produced using three different equipments, being the 
fundamental production process ionotropic gelation. However, since the formation of the 
microspheres occurred at pH 9.0, also coacervation of the chitosan chains occurs. Initially, a 
qualitative analysis was performed, followed by a quantitative analysis on those conditions 
apparently promising, until the condition presenting the 50 µm average diameter 
microspheres was selected. Chitosan microspheres characterization was performed recurring 
to microscopy and laser diffraction techniques. 
4.1.1  High voltage electrostatic system 
The effect of chitosan concentration and flow rate on the chitosan microspheres 
production was evaluated for both chitosan with DA of 6% (Table 5) and 16% (Table 6) using 
high voltage electrostatic system. A qualitative analysis was performed based on the average 
diameter and morphology.  
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Table 5 - Chitosan microspheres images obtained by optical microscopy (scale bar 200 µm). 
Different concentrations of chitosan solution (0.5%, 1% and 1.5% (w/v)) with DA of 6% and different flow 
rates (20, 10, 1 and 0.4 mL/h) are shown. Average diameter is indicated below each condition.  
  Flow rate 
  20 mL/h 10 mL/h 1 mL/h 0.4 mL/h 
C
h
it
o
sa
n
 c
o
n
c
e
n
tr
a
ti
o
n
 
0
.5
 %
 (
w
/v
) 
Mainly one population, 
~130 µm 
Mainly one population, 
~150 µm 
Mainly one population, 
~145 µm 
Mainly one population, 
~131 µm 
1
 %
 (
w
/v
) 
Several sizes, 105-180 
µm 
Mainly one population,~130 
µm  
Mainly two populations, 
~50 µm and 115-160 µm 
One population, 145–180 
µm 
1
.5
 %
 (
w
/v
) 
Mainly one population, 
90-150 µm 
115-180 µm Two populations, 15-35 µm 
and 120-190 µm 
One population, 100–150 
µm 
 
Regarding chitosan with DA of 6% (Table 5), all chitosan microspheres present a uniform, 
spherical morphology, with what seems a denser region in the centre when comparing to the 
periphery (clearer and therefore less dense). Images from optical microscopy (OM) suggest 
that the production of chitosan microspheres is not affected by the variation of the chitosan 
concentration or flow rate, maintaining approximately similar sizes amongst all conditions 
(130-160 µm). Moreover, mostly one population is found in each condition, presenting a 
narrow size distribution.  
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Table 6 - Chitosan microspheres images obtained by optical microscopy (scale bar 200 µm). 
Different concentrations of chitosan solution (0.5%, 1% and 1.5% (w/v)) with DA of 16% and different 
flow rates (20, 10, 1 and 0.4 mL/h) are shown. Average diameter is indicated below each condition.  
 Flow rate 
C
h
it
o
sa
n
 c
o
n
c
e
n
tr
a
ti
o
n
 
 20 mL/h 10 mL/h 1 mL/h 0.4 mL/h 
0
.5
 %
 (
w
/v
) 
Aggregates, impossible to 
identify mics 
Aggregates, impossible to 
identify mics 
Aggregates, impossible to 
identify mics 
Aggregates, impossible to 
identify mics 
1
 %
 (
w
/v
) 
One population,~130 µm One population,~130-150 
µm 
One population, around 
120-140 µm 
One population, around 
105-120 µm 
1
.5
 %
 (
w
/v
) 
One population, 90-120 
µm 
One population, around 
~115µm 
One population around 100-
110 µm 
One population around 110-
125 µm 
 
Regarding chitosan with a DA of 16% (Table 6), it can be seen that at in the lowest 
chitosan concentration (0.5% (w/v)) there is no identification of microspheres, only 
aggregates are seen. Nevertheless, when increasing the concentration to 1% and 1.5% (w/v), 
the formation of spherical and structural homogeneous microspheres is observed throughout 
the conditions (chitosan concentration of 1 % and 1.5 % (w/v)). Similar diameters are also 
found amongst all the conditions, suggesting once again that flow rate is not a differentiating 
variable in this process.  
Over viewing the previous results, a brief comparison between DA denotes an evident 
difference regarding the morphology of the chitosan microspheres, though similarities 
regarding the spherical shape are observed. Microspheres produced with chitosan of DA 6% 
seem to present a heterogeneous internal density, with the centre being darker and 
therefore denser than the periphery, while when produced with chitosan with DA of 16%, a 
homogeneous structure was formed. This may be related to the number of free primary 
amine groups (–NH2) that confer chitosan its almost unique properties of being positively 
charged. Moreover, the nature and extent of ionic reactions were found to be sensitive to 
variables such as charge density of both electrolytes [98], in this case chitosan and TPP, 
leading to different types of the chitosan-TPP complexes. When chitosan solutions are 
dropped into TPP solutions, gelled spheres are formed instantaneously: negative ions in TPP 
solution diffuse into chitosan droplets interacting with the positive amines on the chitosan 
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chain. If more amines are available to react, which is the case of chitosan with DA of 6%, for 
the same amount of negative ions, TPP may have difficulty to penetrate the droplet of 
chitosan, thus forming an external wall preventing the centre to proper reticulate. For DA of 
16%, since less amines are available, a graduate formation of inter and intra molecular 
interactions occurs, leading to the formation of a compact structure [98]. However, in order 
to better understand whether this difference is actually due to the different density inside 
the microspheres or due to the passage of the light through different thicknesses, 
cryosections would have to be performed and analyzed. 
Moreover, and regarding size, a slightly decrease on the average diameter is noticed 
when increasing the DA from 6% (around 150 µm) to 16% (around 115 µm), perhaps due to less 
repulsion between chitosan chains with DA of 16%. 
 
Overall, the chitosan concentration and the flow rate do not seem to have particularly 
influence on the production process using high voltage electrostatic system. However, 
chitosan DA appear to be an influent factor on the chitosan microspheres production process, 
changing their final characteristics. Since chitosan microspheres produced are bigger (115-
150 µm) than desired, this system was considered not appropriate to continue the studies. 
4.1.2  Co-axial air stream system 
Regarding the droplet extrusion under co-axial air stream method, Tables 7, 8 and 9 
gather the images obtained by optical microscopy for chitosan with DA of 6% at a 
concentration of 0.5%, 1% and 1.5% (w/v), respectively, for an increasing air stream pressure 
of 0.25, 0.4, 0.6 and 1 bar and flow rate of the syringe of 1, 10 and 20 mL/h. Tables 10, 11 
and 12 represent the same analysis but for chitosan with DA of 16%. 
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Table 7 - Chitosan microspheres images obtained by optical microscopy (scale bar 200 µm). 
Variation of the flow rate (20, 10, 1 mL/h) and air stream pressure (0.25, 0.4, 0.6 and 1 bar) regarding 
chitosan solution concentration of 0.5% (w/v)) and DA of 6% is shown. Average diameter is indicated 
below each condition.  
Flow rate 
0.5% 
(w/v) 
1 mL/h 10 mL/h 20 mL/h 
A
ir
 s
tr
e
a
m
 p
re
ss
u
re
 
0
.2
5
 b
a
r 
---- 
Two populations: 50 µm and 260 
µm  
Three populations: 70 µm, 115 
µm and 215 µm 
0
.4
 b
a
r 
Several populations: 50, 150-200 
and 300 µm  
Several populations, mainly 
between 50 µm and 215 µm  
Three populations: 20-60, 60-
100 and 150-200 µm 
0
.6
 b
a
r 
Several populations: 20-60, 100-
150 and 200 µm 
Several populations, mainly 
between 30 µm and 160 µm 
Several populations, but few 
>150 µm 
1
 b
a
r 
Several sizes, 20-80 µm and few 
120-140 µm  
Several populations, mainly three: 
15, 50 and 130 µm 
---- 
 
Regarding chitosan solution concentration of 0.5% (w/v) (Table 7), microspheres with 
different morphologies and sizes can be observed throughout all the conditions evaluated. 
Chitosan microspheres present a more irregular shape, becoming less spherical when air 
stream pressure is increased. Moreover, different internal structures are observed even 
within the same condition, with microspheres presenting different roughness, shape and 
internal density and size.  
Smaller chitosan microspheres are produced when increasing the air stream pressure, 
nevertheless a wide particle size distribution is observed even within the same condition. 
Despite obtaining particles with sizes closer to the 50 µm envisaged, at least another big 
population (>100 µm) is also observed. 
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Table 8 - Chitosan microspheres images obtained by optical microscopy (scale bar 200 µm). 
Variation of the flow rate (20, 10, 1 mL/h) and air stream pressure (0.25, 0.4, 0.6 and 1 bar) regarding 
chitosan solution concentration of 1 % (w/v)) and DA of 6% is shown. Average diameter is indicated 
below each condition.  
Flow rate 
1 % 
(w/v) 
1 mL/h 10 mL/h 20 mL/h 
A
ir
 s
tr
e
a
m
 p
re
ss
u
re
 
0
.2
5
 b
a
r 
Several sizes, 10-30 µm (mainly) 
and 110-250 µm 
---- ---- 
0
.4
 b
a
r 
Two populations: 20-35 µm and 
~200 µm 
Three populations: 15-30, 100-150 
and ~220 µm 
Two populations: 30-70 µm and 
210 µm 
0
.6
 b
a
r 
Several sizes, 10-20 (higher 
amount), 70-100, 140-190 µm 
Several sizes, 10-20 (higher 
amount),70-95 and 120-160 µm 
Two populations: 20-75 µm and 
130-170 µm 
1
 b
a
r 
Mainly two populations: 10-15 
µm and 70-100 µm 
Several sizes: higher amount of 10-
20, some 35-60 and few 130 µm 
Mainly small population of 13-25 
µm, few 50-110 µm 
 
Morphologically, 1% (w/v) chitosan microspheres are similar amongst conditions and 
within each particular condition, presenting a spherical shape with heterogeneous internal 
density, with the centre being darker, and therefore denser, than the periphery.  
Regarding average diameter, a similar trend to the previous conditions can be observed: 
by increasing air stream pressure, smaller microspheres are produced. However, mainly one 
or two populations are identified, and despite a smaller population (10-30 µm) is observed 
throughout all the conditions, big microspheres are also observed. 
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Table 9 - Chitosan microspheres images obtained by optical microscopy (scale bar 200 µm). 
Variation of the flow rate (20, 10, 1 and 0.4 mL/h) and air stream pressure (0.25, 0.4, 0.6 and 1 bar) 
regarding chitosan solution concentration of 1.5% (w/v)) and DA of 6% is shown. Average diameter is 
indicated below each condition.  
Flow rate 
1.5% 
(w/v) 
0.4 mL/h 1 mL/h 10 mL/h 20 mL/h 
A
ir
 s
tr
e
a
m
 p
re
ss
u
re
 
0
.2
5
 b
a
r 
Several sizes, 20-90 
(mainly), ~200 and 300-
400 µm 
~20 µm , 65-230 µm  and 
380-400 µm 
Several sizes, 30-50, ~170 
and ~350 µm 
Several sizes, 18-50, 
100-150 and ~330 µm 
0
.4
 b
a
r 
 Several sizes: 20-70 µm, 
120-140 µm and 200 µm 
(few) 
Mainly two populations: 20-
50 µm and 160-200 µm  
Several sizes: 20-400 µm 
 
Several sizes, 10-30 and 
few, 60-120 and 200-290 
µm 
0
.6
 b
a
r 
Mainly one population, 15-
25 µm 
Several sizes, 15-40 µm  and 
90-230 µm 
20-40 µm and 80-115 µm. 
Some agglomerates were 
found 
Mainly three 
populations, 10-35, 70-
120 and 220-280 µm 
1
 b
a
r 
Mainly ~15 µm, with some 
linked microspheres 
Mainly around ~10 µm, 
some between 25-60 µm 
15-40 µm Mainly around 10-20 µm, 
with few ~130 µm 
 
When increasing the chitosan concentration to 1.5% (w/v), microspheres seem to present 
a homogeneous distribution of the chitosan, reducing the differences concerning their 
internal structure. A good sphericity is also observed throughout all the conditions. 
Regarding size distribution, and despite the fact that the influence of the air stream 
pressure remains the same as in the previous set of conditions, smaller microspheres are 
produced. At 0.25 bar, though, bigger microspheres are found when comparing to the ones 
identified with chitosan of 0.5% and 1% (w/v).  
Overall, though the air stream pressure seems to have the same effect regardless the 
chitosan concentration, leading to the production of smaller and less spherical microspheres, 
differences are observed when the chitosan concentration is altered, particularly from 0.5% 
to 1% and 1.5% (w/v). When increasing the latter variable, sphericity of microspheres is 
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increased, presenting also a narrower size distribution, with some populations within the 
range aimed.  
The irregularity of the particles may not be, however, a disadvantageous characteristic, 
since it is not mandatory that the particles wished to be obtained actually have a spherical 
shape. A rough surface may also be beneficial, since the surface contact area is increased.  
Even though some conditions have chitosan microspheres within the aimed size ranged, 
the separation of those populations could reduce the production efficiency, since a high 
amount of chitosan would be lost. 
 
As previously referred, chitosan with DA of 16% was also used to produce microspheres in 
this system.  
 
Table 10 - Chitosan microspheres images obtained by optical microscopy (scale bar 200 µm). 
Variation of the flow rate (20, 10, 1 and 0.4 mL/h) and air stream pressure (0.25, 0.4, 0.6 and 1 bar) 
regarding chitosan solution concentration of 0.5% (w/v)) and DA of 16% is shown. Average diameter is 
indicated below each condition. 
Flow rate 
0.5% 
(w/v) 
0.4 mL/h 1 mL/h 10 mL/h 20 mL/h 
A
ir
 s
tr
e
a
m
 p
re
ss
u
re
 
0
.2
5
 b
a
r 
 
 
 
 
 
 
 
 
 
 
0
.4
 b
a
r 
 
 
 
 
0
.6
 b
a
r 
 
 
  
 
 
 
 
 
 
1
 b
a
r 
  
  
 
 
 
 
 
 
 
Regarding DA of 16%, at 0.5% (w/v) chitosan concentration (Table 10), the same outcome 
as obtained in the high voltage electrostatic system was obtained: no identifiable 
microspheres are seen, only aggregates. This may suggest that the conjugation of a low 
chitosan concentration and a smaller number of free amines seems to unable the formation 
of a microsphere. 
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When increasing the concentration to 1% and 1.5% (w/v), individualized microspheres are 
produced (Table 11 and Table 12).  
 
Table 11 - Chitosan microspheres images obtained by optical microscopy (scale bar 200 µm). 
Variation of the flow rate (20, 10, 1 and 0.4 mL/h) and air stream pressure (0.25, 0.4, 0.6 and 1 bar) 
regarding chitosan solution concentration of 1% (w/v)) and DA of 16% is shown. Average diameter is 
indicated below each condition. 
Flow rate 
1% 
(w/v) 
0.4 mL/h 1 mL/h 10 mL/h 20 mL/h 
A
ir
 s
tr
e
a
m
 p
re
ss
u
re
 
0
.2
5
 b
a
r 
 
 
 
 
 
 
 
Mainly two populations, 
250-300 µm (higher 
amount) and 90-150 µm 
 
 
 
 
 
 
 
Mainly two populations, 
higher amount of ~300 
µm, fewer 120-190 µm 
 
 
 
 
 
 
 
Mainly ~300-340 µm, few 
small ones 
 
 
 
 
 
 
 
 
Mainly two populations: 
250-320 and 100-180 µm 
0
.4
 b
a
r 
 
 
 
 
 
 
 
Mainly two populations, 
70-100 µm and 230-250 
µm (higher amount) 
 
 
 
 
 
 
 
Several sizes, 90-160 µm  
and 200-250 µm 
 
 
 
 
 
 
 
Several sizes, 70-120 µm 
and 170-250 µm 
 
 
 
 
 
 
 
Two populations,120-
160 µm and 240-260 µm 
0
.6
 b
a
r 
 
 
 
 
 
 
Several sizes, 150-200 
µm and 60-100 µm 
 
 
 
 
 
 
Several sizes 160-210 µm 
and 70-100 µm 
 
 
 
 
 
 
Several sizes, few 70-160 
µm 
 
 
 
 
 
 
Several sizes, 120-170 
µm and agglomerated 
50-100 µm 
1
 b
a
r 
 
 
 
 
 
 
Similar size, 55-90 µm 
 
 
 
 
 
 
One population, 70-100 
µm with few ~170 µm 
 
 
 
 
 
 
Several sizes, 20-50 µm 
and 100-150 µm 
 
 
 
 
 
 
Several sizes: 50-130 µm 
 
At 1% (w/v) chitosan concentration (Table 11), chitosan microspheres present a different 
distribution regarding size and shape between conditions. At 0.25 bar the microspheres are 
spherical and internally similar, however by increasing the air stream pressure the 
microspheres become smaller, more irregular and with different internal structures. The flow 
rate does not particularly seem to influence size or morphology. 
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Table 12 - Chitosan microspheres images obtained by optical microscopy (scale bar 200 µm). 
Variation of the flow rate (20, 10, 1 and 0.4 mL/h) and air stream pressure (0.25, 0.4, 0.6 and 1 bar) 
regarding chitosan solution concentration of 1.5% (w/v)) and DA of 16% is shown. Average diameter is 
indicated below each condition. 
Flow rate 
1.5% 
(w/v) 
0.4 mL/h 1 mL/h 10 mL/h 20 mL/h 
A
ir
 s
tr
e
a
m
 p
re
ss
u
re
 
0
.2
5
 b
a
r 
 
 
 
 
 
Several sizes: 40-75 µm, 
230-260 µm and 300-350 
µm 
 
 
 
 
 
Two populations: 50-100 
µm  and 280-310 µm 
 
 
 
 
 
Mainly 250-300 µm 
 
 
 
 
 
Several populations, 
~320 µm, ~100 µm and 
~40 µm 
0
.4
 b
a
r 
 
 
 
 
 
Several sizes, 30-80 µm, 
100-150 µm and 200-250 
µm 
 
 
 
 
 
Several sizes, mainly 35-
80 µm, 100-150 µm and 
200-250 µm 
 
 
 
 
 
Several sizes, mainly 55-
80 µm  and 180-250 µm  
 
 
 
 
 
Mainly small ones 35-65 
µm with few 155-250 
µm 
0
.6
 b
a
r 
 
 
 
 
 
20-70 µm  and 100-140 
µm 
 
 
 
 
 
Several sizes, mainly 20-
75 µm and 100-190 µm 
 
 
 
 
 
Two populations: 20-40 
µm and 80-150 µm 
 
 
 
 
 
 Mainly small ones 20-70 
µm, but few ~155 µm 
1
 b
a
r 
 
 
 
 
 
Mainly 10-20 µm and 30-
70 µm 
 
 
 
 
 
15-30 µm (higher 
amount), 50-80 µm and 
100-140 µm 
 
 
 
 
 
Two populations: 20-30 
µm and 60-125 µm 
 
 
 
 
 
Mainly small ones: 15-30 
µm, 40-80 µm and 90-
110 µm (few) 
 
By increasing even more the chitosan concentration to 1.5% (w/v), smaller and spherical 
microspheres are produced throughout all the conditions. While the effect of flow rate is not 
so evident, the effect of the air stream pressure is relevant to the structure of the 
microspheres: at higher pressures smaller microspheres are formed, with spherical shape and 
similar internal structure. A wide distribution regarding sizes is still observed, with a smaller 
population present in all conditions. 
Regarding the influence of chitosan DA, the same trend as observed with high voltage 
electrostatic system is observed: chitosan microspheres with DA of 16% present a consistent 
structure and generally are more spherical and structurally homogeneous than chitosan 
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microspheres produced with chitosan of 6% DA. The latter leads to more disrupted, 
heterogeneous microspheres, although the size does not vary significantly.  
Air stream pressure is a variable that also seems to influence the characteristics of the 
chitosan microspheres produced by co-axial air stream system, where smaller particles are 
produced when air pressure is increased. This trend is observed in all chitosan concentrations 
evaluated and may be related to the unstable formation of the microspheres at higher air 
pressures, which also leads to the production of more irregular particles.  
 
OM qualitative screening of chitosan microspheres produced by co-axial air stream system 
suggested some conditions with diameters within the aimed range of 50 µm. Since 
microspheres with lower DA are expected to be more mucoadhesive and bind more bacteria, 
preference was given to chitosan with DA of 6%. Therefore, a deeper analysis was conducted 
using the IN Cell Analyzer high-throughput imaging and high-content analysis system. Chitosan 
microspheres produced with chitosan concentration of 1% and 1.5% (w/v) and with DA of 6% 
were selected and their size distribution is shown in Table 13 and 14, respectively. 
Histograms shown are the result of the steps referred in section 3.  
Image acquisition by IN Cell Analyzer high-throughput microscopy brings several 
advantages over OM, mainly due to the automated screening of the wells, therefore avoiding 
the manual arrangement of the plate. The autofocus option is also a valuable tool, fastening 
the acquisition process; however, it works better if a black plate is used. If using white 
plates, images on the periphery of the well are not collected correctly and a segmentation of 
the well needs to be done, applying the autofocus option to each area.   
It is important to notice that although most of the microspheres are target as 
individualized ones, aggregates and overlapping microspheres are considered as one 
microsphere, thus wrongly contributing to the average diameter of the condition. Therefore, 
although this software allows a faster and more comprehensive analysis, it is difficult to 
assure that the created protocol targets each one and only microspheres. This problem could 
be overcome if a relative small amount of microspheres is assessed and if they are not 
aggregated, therefore detecting each microsphere as an individual. Indeed, despite the 
valuable imaging system, data analysis may be a time consuming process until de protocol is 
defined.  
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Table 13 – Size distribution of chitosan microspheres produced with chitosan concentration of 1% 
(w/v) and DA of 6%. Data obtained by IN Cell Analyzer analysis software. 
1% 
(w/v) 
1 mL/h 10 mL/h 20 mL/h 
0
.2
5
 b
a
r 
 
 
 
 
 
 
 
 
--- 
 
--- 
0
.4
 b
a
r 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
.6
 b
a
r 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 b
a
r 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Despite not being very evident, IN Cell Analyzer results do correlate with the trend 
observed in OM images. By increasing the air stream pressure, the number of microspheres 
bigger than 60 µm seems to decrease while the number within the range 10-40 µm seems to 
increase. A population of 0-10 µm can be identified in all the evaluated conditions. Moreover, 
the amount of smaller microspheres, especially from 10-40 µm, is always higher than the 
remaining size ranges.  
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Table 14 - Size distribution of chitosan microspheres produced with chitosan concentration of 1.5% 
(w/v) and DA of 6%. Data obtained by IN Cell Analyzer analysis software. 
1.5% 
(w/v) 0.4 mL/h 1 mL/h 10 mL/h 20 mL/h 
0
.2
5
 b
a
r 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
.4
 b
a
r 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
.6
 b
a
r 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
 b
a
r 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regarding 1.5% (w/v) chitosan concentration, the size range described with OM presents 
some similarities with the data shown in Table 14. It can be seen that generally by increasing 
the air stream pressure, the amount of chitosan microspheres with relative bigger sizes are 
reduced, dominating the range size of 10-40 µm in all conditions. However not many 
microspheres bigger than 60 µm are found in the lowest air stream pressure, contrary to the 
OM results.   
 
The fact that data obtained by the IN Cell Analyzer does not exactly correlate with the 
average diameter determined by OM is somehow expected. First, regarding the latter 
method, only few microspheres were assessed, and therefore the reduced number does not 
allow drawing statistically significant conclusions regarding size. Though it might indicate the 
average range of diameters, it is not an absolute data. Furthermore, the way average 
diameters are calculated in both methods is different. While in OM a straight line is manually 
draw horizontally from one point to the other of the microsphere, the IN Cell Analyzer 
software determines the average diameter as the mean of all internal diameters 
perpendicular to the maximum centre line through the microsphere, automatically. 
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Moreover, in the latter equipment microspheres on the border of each image are 
automatically excluded, although this may not have such influence, because the number of 
excluded microspheres may be distributed over the size range. 
4.1.3  Aerodynamically driven system 
Finally, results of microspheres produced using the aerodynamically driven system are 
reported. Focusing on the DA of 6%, a screening was performed to several conditions, varying 
the nozzle diameter of the equipment, air stream pressure and flow rate for two chitosan 
concentrations, 0.5% (Table 15) and 1% (w/v) (Table 16). OM analysis was not carried on since 
Mastersizer equipment presents particle size distributions in a faster and less time consuming 
way.  
 
Table 15 – Mastersizer analysis of size distribution of chitosan microspheres (DA 6%) produced by 
aerodynamically driven system with nozzle diameter of 0.25 mm. Histogram (relating size classes and 
volume (%)) and corresponding volume percentiles (Dv10, Dv50 and Dv90) are shown. XX axis represents 
the size classes (µm - 10, 100 and 1000 marks are shown). 
 Flow rate 
Nozzle 
0.25 mm 0.25mL/min 0.33mL/min 0.5mL/min 1mL/min 
0
.5
 %
 (
w
/v
) 
4
1
5
 m
B
a
r 
---- ---- 
 
 
 
 
 
Dv10 = 26 µm 
Dv50 = 81.2 µm 
Dv90 = 1390 µm 
---- 
5
2
5
 m
B
a
r 
Agglomerates ---- 
 
 
 
 
 
 
Dv10 = 20.4 µm 
Dv50 = 55.2 µm 
Dv90 = 331 µm 
 
 
 
 
 
 
Dv10 = 23.3 µm 
Dv50 = 51.0 µm 
Dv90 = 224 µm 
1
 %
 (
w
/v
) 
2
5
5
 m
B
a
r 
 
 
 
 
 
 
Dv10 = 66.8 µm 
Dv50 = 203 µm 
Dv90 = 361 µm 
---- 
 
 
 
 
 
 
Dv10 = 70.7 µm 
Dv50 = 222 µm 
Dv90 = 387 µm 
 
 
 
 
 
 
Dv10 = 26.7 µm 
Dv50 = 115 µm 
Dv90 = 239 µm 
4
1
5
 m
B
a
r 
---- ---- 
 
 
 
 
 
 
Dv10 = 28.4 µm 
Dv50 = 104 µm 
Dv90 = 178 µm 
---- 
5
2
5
 m
B
a
r 
 
 
 
 
 
 
Dv10 = 41.2 µm 
Dv50 = 159 µm 
Dv90 = 305 µm 
 
 
 
 
 
 
Dv10 = 33.4 µm 
Dv50 = 101 µm 
Dv90 = 240 µm 
 
 
 
 
 
 
Dv10 = 23.9 µm 
Dv50 = 79.6 µm 
Dv90 = 145 µm 
 
 
 
 
 
 
Dv10 = 34.2 µm 
Dv50 = 145 µm 
Dv90 = 216 µm 
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Data collected by the Mastersizer includes the histogram with the volume weighted 
particle size distributions and the percentiles regarding the maximum particle size for a given 
percentage volume of the sample (Dv10, Dv50 and Dv90). Overall, this information suggests 
that a wide size distribution (20-400 µm) can be obtained by aerodynamically driven system 
through variation of the different parameters. The percentage of particles smaller than 20 
µm is small, and mostly two populations are found in each condition, with one generally in 
higher amount.  
However, by increasing the air pressure (from 415 to 255 mBar and 525 mBar), a decrease 
in the Dv50 is observed for both concentrations, particularly at 1% (w/v) chitosan 
concentration (~200 µm), where a clear shift to the left is seen on the histogram. Regarding 
the effect of the flow rate, a pattern is not found between the conditions under the same 
pressure, suggesting that this parameter does not influence the chitosan microspheres 
production considerably. 
When comparing chitosan concentrations, it can be observed that at 0.5% (w/v) chitosan 
particles present smaller sizes, with a Dv50 of around 50 µm at the highest air stream 
pressure. At 0.5 mL/min two clear and defined populations can be observed for both 
evaluated pressures. By increasing concentration to 1% (w/v), it can be seen an increase on 
the Dv50 values throughout all the samples.  
 
Table 16 - Mastersizer analysis of size distribution of chitosan microspheres produced by 
aerodynamically driven system with nozzle diameter of 0.5 mm. Histogram (relating size classes and 
volume (%)) and corresponding volume percentiles (Dv10, Dv50 and Dv90) are shown. XX axis represents 
the size classes (µm - 10, 100 and 1000 marks are shown). 
Nozzle  
0.5 mm 0.25 mL/min 0.33 mL/min     0.5 mL/min 1.5 mL/min 
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Dv10 = 52.2 µm  
Dv50 = 208 µm 
Dv90 = 495 µm  
 
 
 
 
 
Dv10 = 35.6 µm  
Dv50 = 157 µm  
Dv90 = 310 µm 
 
 
 
 
 
Dv10 = 36.1 µm  
Dv50 = 157 µm  
Dv90 = 322 µm  
---- 
   
Altering the nozzle diameter of the equipment seems to be a preponderant factor, since 
at 1% (w/v) chitosan concentration is verified a significant increase on the particles diameter 
when comparing with the same concentration but with the smaller nozzle diameter (0.25 
mm). A clear shift to the right on the histogram is observed, showing an increase in all the 
percentiles, for both low (255 mBar) and high (525 mBar) air pressures.  
 
Microspheres produced with higher pressure (525 mBar) and nozzle diameter of 0.25 mm, 
and therefore smaller, were further used for size and morphology analysis in IN Cell Analyzer 
imaging system (Table 17 and 18).  
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Table 17 – IN Cell Analyzer size distribution of chitosan microspheres (DA 6%) produced in the 
aerodynamically driven system with 0.25 mm nozzle under higher pressure (525 mBar). 
Nozzle 
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The effect of the chitosan concentration on the characteristics of the chitosan 
microspheres produced is once again observed with the IN Cell Analyzer high-throughput 
microscope. At the highest pressure (525 mBar) and with the 0.25 mm nozzle, chitosan 
particles present a bigger size when a higher chitosan concentration is used (1% (w/v)). It can 
be observed that with 0.5% (w/v) chitosan particles range mainly between 0-40 µm, with 
some amount between 40-60 µm. When increasing the concentration to 1% (w/v), the trend 
observed on the IN Cell Analyzer analysis is repeated and an increase on the average size of 
the particles is observed: the number of particles between 0-40 µm is reduced, increasing the 
number of particles within the range 40-60 µm and >60 µm. Flow rate 0.5 mL/min at 525 
mBar represents the condition with the smaller Dv50, trend proven by this analysis as well. 
Differences regarding chitosan microspheres morphology are also evident, being the 
microspheres produced with 1% (w/v) chitosan concentration more spherical and 
homogeneous than the ones produced using the low concentration.   
When comparing the results from both IN Cell Analyzer and Mastersizer analysis, a 
correlation can be established. Concerning nozzle 0.25 mm and chitosan concentration of 1% 
(w/v), at 0.33 mL/min the Dv50 is 101 µm, meaning that 50% of the particles have a size 
below that value. This also means that more particles would be represented in the graph in 
the range 40-60 µm and > 60 µm than in the 0.5 mL/min condition, where the Dv50 is 79.6 
µm, and therefore higher amount of particles are smaller. When comparing nozzle 0.5 mm 
condition for the same chitosan concentration and flow rate values, both graphs are similar 
as well as the percentiles. At 0.33 and 0.5 mL/min the Dv50 is 157 µm, with only 10% of the 
particles smaller than 35.6 µm and 36.1 µm, respectively. This average sizes would be within 
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the size range of 0-10 and 10-40 µm in the Mastersizer graphs, but in a smaller amount than it 
actually is. Differences regarding both analyses may be explained given the fact that though 
it is possible to convert particle size data from one type of distribution to another, this 
requires certain assumptions about the form of the particle and its physical properties. 
Therefore, a volume weighted particle size distribution measured using image analysis may 
not necessarily agree exactly with a particle size distribution measured by laser diffraction. 
Nevertheless, the data collected by both methods is complementary, with the IN Cell 
Analyzer high-throughput imaging system having a particular relevance regarding assessment 
of chitosan microspheres morphology. 
 
The optimization process of chitosan microspheres production narrowed the options and 
allowed identifying the aerodynamically driven system (Var J30), in conjugation with the 
parameters specified on Table 18, as the suitable one for the production of 50 µm diameter 
chitosan microspheres. This system was preferred over co-axial air stream system, mainly due 
to the speed of the production process.  
 
Table 18 – Set of parameters applied in encapsulation system Var J30 for production of 50 µm 
chitosan microspheres.  
Degree of Acetylation 6% 
Chitosan concentration 0.5% (w/v) 
Nozzle 0.25 mm 
Flow rate 0.5 mL/min 
Air pressure 525 mBar 
  
The average size and the size distribution of the chitosan microspheres were determined 
by different methods, which results are shown in Figure 8.  
 
 
 
 
 
 
 
 
Figure 8 – Size distribution of chitosan microspheres in TPP after ionotropic gelation evaluated by 
Mastersizer (A), optical microscopy (B, scale bar 100 µm) and IN Cell Analyzer high-throughput 
microscopy (C, scale bar 50 µm).  
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Particle size distribution was firstly collected based on a laser diffraction technique 
(Figure 8, A), where 50% of the particles were found to have a size below 55.2 µm. Optical 
microscopy was also used to assess chitosan microspheres morphology (Figure 8, B) and 
images were used to manually evaluate the average diameter of the microspheres (43.9 µm). 
Moreover, images obtained by IN Cell Analyzer high-throughput microscopy allowed a manual 
measurement of the average diameter of the microspheres (40.4 µm) (Figure 8, C); through 
an automatic analysis the majority of the microspheres were placed within the 10-40 µm 
range. 
Despite the different characterization techniques, the average sizes obtained were 
similar. 
4.2 Genipin crosslinking  
Being a relevant and determinant factor for chitosan microspheres properties regarding 
stability in acidic conditions and mucoadhesion, the crosslinking degree of chitosan 
microspheres was evaluated by time-lapse using fluorescence microscopy.  
Figure 9 shows the fluorescence behaviour of the first two hours of chitosan microspheres 
incubation with 10 mM genipin. Previous studies have determined 10 mM of genipin as the 
adequate concentration, since the reaction time required for crosslinking was shorter and 
with higher fluorescence levels when compared to 1 mM of genipin [108].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Genipin crosslinking           45 
 
Mean of Timelapse 1 and 2
0 1 2 3
0
500
1000
1500
2000
Time (h)
D
e
n
s
it
o
m
e
tr
ic
 m
e
a
n
 
A 0:00 0:15 0:30 
 
   
 0:45 1:00 1:15 
 
 
  
 1:30 1:45 2:00 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 - Fluorescence microscopy images of chitosan microspheres crosslinked with 10 mM genipin 
(A). The time of crosslinking (h) is represented on the top of each image, scale bar 100 µm. Crosslinking 
kinetic of chitosan microspheres in the presence of 10 mM genipin (B) 
 
Results have shown an increase of fluorescence intensity with crosslinking time for the 
genipin concentration tested (10 mM), reaching a plateau after approximately 1h15min of 
reaction.  
Since chitosan mucoadhesive properties are dependent of the amount of primary amines 
available in the chitosan chain, the crosslinking process must be controlled. For that reason, 
45 min was established as enough time to assure that the microspheres do not dissolve in 
acidic conditions, while maintain their mucoadhesive properties conferred by the free 
amines. As such, after crosslinking of chitosan microspheres genipin 10 mM for 45 min, they 
were submitted to lyophilisation.  
Figure 10 shows the morphology of the microspheres before (A) and after (B) the 
crosslinking and lyophilisation (followed by hydration). 
A C 
B 
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Figure 10 - IN Cell Analyzer images of chitosan microspheres before (A) and after (B) crosslinking 
and lyophilisation and hydration. Scale bar 50 µm. 
 
Images obtained by IN Cell Analyzer high-throughput microscopy revealed an evident 
change in chitosan microspheres morphology, with lyophilised microspheres presenting a 
rather irregular, rough structure, with reduced sphericity.  
An intensive characterization was performed by IN Cell Analyzer, with a strict analysis on 
the Spotfire™ DecisionSite™. Average diameter, maximum chord, form factor and area are 
some of the parameters measured, graphically represented below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Both graphs on Figure 11 represent similar data concerning size distribution of chitosan 
microspheres, although the left graph shows the distribution throughout the 25 fields of the 
well and the right graph the amount of microspheres within each range of sizes. Average 
diameter is calculated as the mean internal distance perpendicular to the maximum curved 
chord, which is the maximum centre line through a target. It can be acknowledged in both 
graphs that size varies from approximately 5 to 60 µm, with the higher amount being 
concentrated around 10-30 µm. Once again, the size of the black dots corresponds to the 
form factor associated to each microspheres. When comparing the average size before and 
after liophilisation, a decrease is observed from 50 µm to around 20 µm. 
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Figure 11 – Average diameter distribution of the individualized chitosan microspheres, after 
lyophilisation. 
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Regarding the morphology, it was observed that the liophilisation process led to a change 
in the shape of the spheres, turning them more irregular and similar to particles. Because the 
particles are not spherical, average diameter may not provide all information regarding 
microsphrees size, and therefore maximum chord may be a valuable information as well. 
Based on Figure 12, most particles present a maximum chord of 50 µm despite ranging 
between 40 and 60 µm, which corresponds to the expected average diameter.  
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Each black dot corresponds to a single chitosan microsphere, throughout the 25 fields 
taken of each well. Regarding the graph on the left, the area of each microsphere is 
represented on the XX axis, revealing that most of chitosan microspheres present an area 
inferior to 1000 µm2. However, the size of each black dot also correlates to its form factor: 
smaller black dots possess a smaller value regarding form factor, and therefore are more 
irregular, while bigger dots correspond to rounder microspheres. This can be also correlated 
to the graph on the right, which shows the distribution of the chitosan microspheres 
regarding their form factor. In this case, the size of the black dots correlates to the area of 
the actual microspheres. The selected dot on both graphs corresponds to the same 
microsphere. 
Figure 13 – Area (left graph) and form factor (right graph) of each chitosan microsphere, after 
lyophilisation. 
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Figure 12 – Maximum chord of chitosan microspheres, after lyophilisation. 
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As such, chitosan microspheres present not only a different morphology but also a 
decrease in the average diameter when comparing to microspheres before lyophilisation. 
Chitosan microspheres present a more irregular structure, with an average diameter around 
20 µm, but with a maximum chord around 50 µm. 
4.2.1 Stability in acidic conditions 
In order to validate the chitosan microspheres for application in the stomach without 
dissolution, their stability under acidic conditions must be evaluated. Given the pH range 
found in the gastric mucosa (from pH 1.2-2.5 in the lumen to neutral at the epithelial surface 
pH ~7.4), a compromise had to be made and pH 6.0 was chosen to conduct the experiments. 
Chitosan microspheres were therefore incubated in pH 6.0 phosphate-citrate buffer and 
their behaviour was followed over 1-h period (Figure 14). 
 
   
  
 
Figure 14 – Optical microscopy images of chitosan microspheres in acidic conditions over 1 h. Scale 
bar 100 µm. 
 
As can be seen in Figure 14, no major differences are observed regarding the morphology 
of chitosan microspheres, suggesting their stability under pH 6.0.  
4.3 Chitosan microspheres emission spectrum 
Fluorescence is probably the best technique to evaluate microspheres capacity to 
penetrate gastric foveolae and to bind H. pylori. As such, understanding chitosan 
microspheres fluorescence properties is fundamental. Microspheres spectrum was evaluated 
by exciting microspheres with different lasers: 405 nm, 488 nm and 561 nm. The spectrum 
corresponding to the excitation of 405 nm is presented below (Figure 15).  
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1:00 
0:00 
0:45 
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By exciting the chitosan microspheres with a 405 nm laser, two peaks can be identified in 
their emission spectrum: a maximum value at 477 nm, followed by a slow decrease in relative 
fluorescence, and an increase again at 627 nm, approximately, though less intense than the 
first peak. This behaviour can be followed on the fluorescence images shown.  
When chitosan microspheres are excited with different lasers (488 nm and 561 nm, data 
not shown), the exact same behaviour can be observed, although only the second peak is 
observed since excitation is made in a wavelength higher than the first emission peak (677 
nm).  
Therefore, these results indicate that independently of the excitation laser, the emission 
spectrum of the chitosan microspheres will be always the same. The microspheres were not 
previously labelled, and consequently this spectrum can also reveal chitosan microspheres 
auto-fluorescence throughout a wide range of wavelength (450 nm to 650 nm, 
approximately). 
4.4 Chitosan microspheres adhesion to gastric mucosa  
Evaluation of the chitosan microspheres capacity of penetrate the gastric mucosa, in 
order to reach deeper H. pylori living inside the gastric foveolae, is one of the main aims 
initially established. Microspheres adhesion studies to gastric mucosa were performed and 
evaluated by Inverted Fluorescence Microscopy and Confocal Laser Scanning Microscopy. 
 
 
Figure 15 - Chitosan microspheres emission spectrum obtained by CLSM when excited by 405 nm laser. 
477 nm 627 nm 582 nm 432 nm 
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4.4.1  Optimization of gastric mucosa labelling 
The direct observation of ex-vivo samples of gastric mucosa would ease the process of 
evaluating the penetration of the chitosan microspheres into the gastric foveolae. Therefore, 
fresh mice stomach samples were used to optimize the fluorescence labelling of gastric 
mucosa.  
Initially, fresh mice gastric mucosas were mounted only with different mounting media 
(Figure 16).  
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Figure 16 – Fluorescence microscopy images of mice gastric mucosa mounted with different 
mounting media. Scale bar 100 µm.    
Figure 16 allows the observation of the tissue, although not in a very clear way. No gastric 
structures are identified, suggesting that auto-fluorescence of the tissue is residual. This 
auto-fluorescence is apparently improved by the usage of Fluoromount as mounting medium, 
although the difference is not evident. Regarding the application of Vectashield with DAPI, 
previous fixation of the tissue with PFA 4% seems to improve its observation when comparing 
to the sample when only Vectashield with DAPI was applied. 
 
DAPI and Hoechst were then tested as nucleic acid stains (Figure 17), while several Wheat 
Germ Agglutinin conjugates and a CellMask™ Deep Red stain were used as plasma membrane 
stains (Figure 18).   
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Figure 17 – Fluorescence microscopy images of mice gastric mucosa stained with nucleic acid dyes 
(with two different concentrations, 1:100 and 1:1000), using two different mounting media. Scale bar 
100 µm.   
 
The blurred image of gastric mucosa labelled with DAPI 1:100 suggests that this staining is 
not strong enough to adequately label the DNA of the mucosa allowing its visualization. The 
same is observed when Hoechst 1:100 is used. However, DAPI is a stain recommended for 
fixed or permeabilized cells. As such, when analysing the fixed mucosa with PFA 4% followed 
labelling with DAPI, bright spots are observed, identifying what seems to be the nucleus of 
the gastric cells of the surface of the mucosa. Comparing the two concentrations of DAPI, a 
clear and brighter image is obtained when the higher concentration (1:100) is used. 
 
Figure 18 shows the fluorescence labelling of gastric mucosa by different plasma 
membrane stains. As previously referred, these samples were kept fresh without adding 
mounting media. Fluorescently labelled lectins, such as WGA, were exploited as plasma 
membrane stains as well as CellMask™ Deep Red.  
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Figure 18 - Fluorescence microscopy images of mice gastric mucosa labelled with different plasma 
membrane staining, at different concentrations and time of incubation (indicated above each image). 
Scale bar 100 µm.    
Over viewing the different WGA conjugates, none successfully labelled the mucosa. 
However, CellMask™ Deep Red stain performs a stronger staining of the plasma membrane of 
the cells from the gastric mucosa. According to the manufacturer, when comparing to 
labelled WGA, CellMask™ Deep Red plasma membrane stain takes more time to be 
internalized, thus maintaining the staining or a longer period. Therefore, this plasma 
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membrane stain has proved to perform an excellent and rapid plasma membrane staining, 
excluding the need of previous fixation and incubation periods. 
 
Based on this first screening, DAPI (fixed sample) and CellMask™ Deep Red plasma 
membrane (fresh) stain were determined as good gastric mucosa markers. In order to better 
assess its feasibility for further adhesion studies, gastric mucosa without labelling (Figure 19), 
and stained with DAPI 1:100 after fixation with PFA 4% (Figure 20) were observed under CLSM 
as well as CellMask™ Deep Red labelled mucosa (Figure 21). Different Z-plans of the mucosa 
were acquired and are represented below.  
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Figure 19 – Auto-fluorescence of mice gastric mucosa in two ranges of emission wavelength. CLSM 
images of the outer layer (Z=1) and deeper layers (Z=10 and Z=17) of mice gastric mucosa (ScanMode 
xyz; step size 2.9 µm). Scale bar 100 µm. 
CLSM images confirm a residual auto-fluorescence of the gastric mucosa, which emits 
fluorescence between 420-552 nm (green) and between 652-772 nm (red). However, the 
emission is not strong enough to properly observe the physical characteristics of the gastric 
mucosa. 
 
Figure 20 illustrates the difference in the gastric mucosa morphology when going deeper 
inside the tissue of the sample fixed with PFA 4% followed labelling with DAPI 1:100. Apart 
from the horizontal section of the tissue, two orthogonal views of two stacks are shown as 
well. The vertical and horizontal images correspond to a perpendicular plan to the one 
visualized from above on the area of the white crosshair.  
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Figure 20 – Mice gastric mucosa fixed with PFA 4% and labelled with DAPI 1:100. CLSM images of the 
outer layer (Z=5) and deeper layers (Z=7 to Z=15) of mice gastric mucosa (ScanMode xyz; step size 9.99 
µm). Orthogonal views of two stacks (Z=9 and Z=15) are shown (ScanMode xzy). Scale bar 100 µm. 
 
Evaluation of the different stacks at different depths suggests the combination of PFA 4% 
with DAPI 1:100 labelling as a good procedure to observe gastric foveolae. Different stacks 
from the same area allow the identification of three gastric foveolae, whose diameter is 
decreased when going deeper into the tissue (from Z=5 to Z=15). On the orthogonal views the 
curvature of the foveolae is also seen (darker region). 
 
CLSM images of different stacks from the CellMask™ Deep Red labelled mucosa are 
gathered on Figure 21. 
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Labelling with CellMask™ Deep Red seems strong enough to clearly observe the mucosa 
and the foveolae. By going deeper inside the tissue, a change in the morphology of the 
mucosa is seen; the structures become darker and the diameter of the dark areas smaller. By 
going inside the tissue, the mucosa ends up with only dark areas, due to a decrease on the 
fluorescence. The orthogonal view shows the corresponding curvature of the foveolae. 
 
Combination of PFA 4% fixation and DAPI 1:100 labelling as well as the CellMask™ Deep 
Red plasma membrane stain allowed a good observation of the gastric mucosa, both by 
fluorescence and confocal microscopy. Therefore, these staining were applied for the 
following studies. 
4.4.2  Chitosan microspheres adhesion to mice gastric mucosa 
Chitosan microspheres adhesion studies to mice gastric mucosa were performed at 37ºC, 
at pH 6.0 and under stirring, in order to mimic the in vivo conditions. Staining was afterwards 
employed considering the results from the last section. 
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Figure 21 – Mice gastric mucosa cells labelled with CellMask™ Deep Red stain. CLSM images of the 
outer layer (Z=7) and deeper layers (Z=12 to Z=36) of mice gastric mucosa (ScanMode xyz; step size 2.6 
µm). Orthogonal views of stack Z=32 is shown (ScanMode xzy). Scale bar 100 µm. 
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Figure 22 shows the gastric mucosa labelled with DAPI 1:100 after fixation with PFA 4%, 
both without (control) and with chitosan microspheres adhered. Figure 23 gathers the same 
information although regarding CellMask™ Deep Red staining. 
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Figure 22 - Fluorescence microscopy images of mice gastric mucosa alone and with chitosan 
microspheres. Mucosa was fixed with PFA 4% followed labelling with DAPI 1:100 in both conditions. Scale 
bar 100 µm.  
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Figure 23 - Fluorescence microscopy images of mice gastric mucosa alone and with chitosan 
microspheres. Mucosa was labelled with CellMask™ Deep Red in both conditions. Scale bar 100 µm.  
 
Both conditions allow the observation of adhered chitosan microspheres, confirming their 
ability to adhere to the gastric mucosa.  
 
In order to evaluate whether chitosan microspheres are able to penetrate the gastric 
mucosa, 3D images are required. Confocal images for both conditions are presented below. 
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Figure 24 concerns the gastric mucosa labelled with PFA 4% DAPI 1:100. DNA of gastric 
cells of the mucosa is labelled in blue, while the microsphere is seen in red. A single 
microsphere was selected and observed closely. Different stacks were taken in order to 
understand the position of the microsphere in relation to the gastric mucosa.  
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Figure 24 – Chitosan microspheres (red) adhered to mice gastric mucosa fixed with PFA 4% and 
labelled with DAPI 1:100 (blue). CLSM images of the outer layer (Z=3) and deeper layers (Z=51 to Z=143) 
of mice gastric mucosa (ScanMode xyz; step size 0.17 µm). Orthogonal views of merged images are 
shown (ScanMode xzy). Scale bar 50 µm. 
 
Different stacks of the mucosa allow a 3D perpective of the latter, in order to understand 
whether the microsphere is inside the mucosa and consequently between the cells (blue). 
Going through deeper stacks it can be seen that in fact the chitosan microsphere (red) 
penetrated the mucosa. At stack Z=3 the presence of  the microsphere is almost 
imperceptible, however when at Z=51 it starts to appear, being some cells visible above the 
microsphere. At Z=103 a complete plan of the microsphere is seen, however at Z=143 it 
disappears, suggesting that the imaging section is already in an area with only cells.  
Figure 25 presents an orthogonal view of a single chitosan microsphere (red), which is 
clearly inserted on the mucosa (blue). 
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Mucosa Ch mics Merge 
   
Figure 25 – Orthogonal view of chitosan microsphere (red) inserted into mice gastric mucosa fixed 
with PFA 4% and labelled with DAPI 1:100 (blue) (ScanMode xzy). Scale bar 50 µm. 
 
Gastric mucosa labelled with CellMask™ Deep Red is seen in Figure 26, showing several 
stacks taken at different depths.  
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Figure 26 - Mice gastric mucosa cells labelled with CellMask™ Deep Red stain with chitosan 
microspheres adhered (red). CLSM images of the outer layer (Z=20) and deeper layers (Z=28 to Z=59) of 
mice gastric mucosa (ScanMode xyz; step size 2.6 µm). Scale bar 100 µm. 
 
Observation of the latter set of images allows identifying the presence of chitosan 
microspheres in different plans. At Z=20, a superficial image taken, an imperceptible 
visualization of the mucosa as well as the microsphere indicates the microspheres ability to 
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penetrate. The following stacks confirm that ability, since when going in the direction of the 
muscle, some microspheres are no longer observed while fluorescence of other microspheres 
is detected. This suggests that microspheres are indeed in different plans of the mucosa, 
being able to cross the remaining mucus layer. 
 
Both stainings allow the identification of 3D depressions corresponding to gastric foveolae 
and chitosan microspheres, revealing the presence of the microspheres not only on the 
superficial plans, but deeper inside the tissue. These images were taken after the rinsing 
step, suggesting the chitosan microspheres as highly mucoadhesive, since they are able to 
remain attached to the fresh mucosa. 
However, in order to mimic the natural conditions closely, fresh samples (without 
fixation) may be preferable as a study model. 
4.4.3  Chitosan microspheres adhesion to human gastric mucosa 
Ultimately, human gastric mucosa was used to evaluate the ability of chitosan 
microspheres to penetrate the tissue.  
Given the good performance as mice gastric mucosa labelling, and since it does not 
require fixation of the tissue or an incubation period, CellMask™ Deep Red plasma membrane 
stain was selected to label the human gastric mucosa previously to observation by CLSM.  
Figure 27 shows the labelling of the human gastric mucosa with CellMask™ Deep Red 
stain. 
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Figure 27 - Human gastric mucosa labelled with CellMask™ Deep Red stain. CLSM images of the 
outer layer (Z=13) and deeper layers (Z=19, Z=25 and Z=29) of human gastric mucosa (ScanMode xyz; 
step size 3.9 µm). Scale bar 100 µm. 
 
Firstly, a different morphology of the tissue can be observed when comparing to the mice 
gastric mucosa previously evaluated. Nevertheless, the marker seems to stain the tissue 
properly, since a clear change is seen when going deeper. A thick layer of mucus was 
observed, shown at Z=13, which starts to disappear when stacks from a higher depth are 
taken. At Z=29 it is observed the presence of a darker area, which may resemble the gastric 
foveolae seen in the mice stomach. However the physiology is different and difficult to 
compare.  
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Chitosan microspheres adhesion studies were also performed using human gastric mucosa, 
at 37ºC, at pH 6.0 and under stirring. Figure 28 shows the same area at different depths. 
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Figure 28 - Human gastric mucosa labelled with CellMask™ Deep Red stain. CLSM images of the 
outer layer (Z=1) and deeper layers (Z=8, Z=17 and Z=28) of human gastric mucosa (ScanMode xyz; step 
size 3.01 µm). Scale bar 100 µm.  
 
Regarding the evaluation of the ability of chitosan microspheres to penetrate the human 
foveolae, it can be observed that most of the particles remain in superficial plans: though a 
depth of around 140 µm was evaluated, chitosan microspheres are no longer observed at a 
depth higher than 84.3 µm (Z=28). In addition, it is important to consider the thickness of the 
mucus layer, which may reduce even more the actual depth penetrated by the chitosan 
microspheres. Nevertheless, it is not known whether the microspheres do not actually 
penetrate or if deeper plans cannot be obtained, because lack of fluorescence, thus revealing 
their presence. When comparing to mice gastric mucosa, around 250 µm depth can be 
observed through CLSM, therefore microspheres in deeper plans can be observed.  
4.5 Helicobacter pylori adhesion to chitosan microspheres 
The ability of chitosan microspheres to adhere to Helicobacter pylori (H. pylori) is also 
important considering the final aim of using chitosan microspheres to remove the bacteria 
from the stomach. Therefore, a study was conducted in vitro using J99 strain of H. pylori 
alive and previously fixed and labelled with FITC, at a pH of 6.0. 
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4.5.1  Adhesion of live H. pylori J99 strain to chitosan 
microspheres 
Because the in vivo adhesion process between the microspheres and the bacteria occurs 
with the bacteria alive, in this study labelling of the bacteria was performed only after the 
2h-period of adhesion. Inverted fluorescence microscopy results are shown in Figure 29. 
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Figure 29 – Fluorescence microscopy images of DAPI, Hoechst and Vectashield with DAPI -labelled 
H. pylori adhered to chitosan microspheres. Scale bar 50 µm.  
 
Apparently, only small dots corresponding to bacteria are seen when Vectashield with 
DAPI is used. When DAPI or Hoechst 1:100 are used no evident differences are found between 
the samples, and the chitosan microspheres are still able to be observed in both channels.   
Figure 30 shows confocal images of a chitosan microsphere with adhered bacteria labelled 
with Vectashield with DAPI.  
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Figure 30 – Maximum projection of a chitosan microsphere with Vectashield with DAPI-labelled 
bacteria. Images were obtained by CLSM. Scale bar 25 µm. 
 
As it can be seen, no dots representing the bacteria are observed. This can mean that 
bacteria did not adhere to the chitosan microsphere, or it can also mean that the auto-
fluorescence of the chitosan particle in the blue wavelength is too intense to detected 
bacteria DNA labelling.  
In order to try to eliminate/reduce the factor of auto-fluorescence, a microsphere 
labelled with Vectashield with DAPI should be used as a control. The minimum blue 
fluorescence would be initially determined, so that when the same settings were applied to 
the labelled sample, the auto-fluorescence was subtracted and the labelled bacteria 
detected. For this, similar microspheres should be used: since they are heterogeneous among 
them, microspheres with different density would contribute differently to the auto-
fluorescence. 
Given this results, it can be said that visualization of live DNA labelled-bacteria is difficult 
by both fluorescence and confocal microscopy, being required a different label method. 
4.5.2  Adhesion of fixed H. pylori J99 strain to chitosan 
microspheres  
The adhesion of FITC-labelled H. pylori to chitosan microspheres at pH 6.0 was evaluated 
by CLSM (Figure 31).  
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Figure 31 - FITC-labelled J99 strain (green) adhered to chitosan microspheres (red) under pH 6.0 
for five z-stacks (Z, step size of 2.98 µm). Images were obtained by CLSM. Scale bar 25 µm. 
In this case, a brighter and stronger signal was detected from FITC-labelled bacteria, 
allowing an easy and clear assessment of the adhesion to the chitosan microspheres. CLSM 
allowed the visualization of stacks of the whole microsphere, revealing that bacteria were 
well distributed all over the surface of the microspheres, though no bacteria were found 
inside the microsphere. The fact that the microsphere presents an irregular and 
heterogeneous surface increases the surface contact area and therefore the number of 
adhered bacteria. 
It is herein demonstrated that chitosan microspheres crosslinked with genipin and 
lyophilised have the capacity to adhere to J99 H. pylori strain under pH 6.0.  
 
 
 
 
  
 
 
 
Chapter 5  
Conclusions and future considerations 
Conclusions  
 
Chitosan microspheres were produced by three different equipments, in order to evaluate 
the influence of different parameters on microspheres features. Overall, when using the high 
voltage electrostatic system the chitosan concentration and the flow rate do not seem to 
influence the production process. However, chitosan DA appears to be an influent factor on 
the chitosan microspheres production process, with chitosan microspheres with DA of 16% 
presenting a consistent structure and generally being more spherical and structurally 
homogeneous than chitosan microspheres produced with chitosan of 6% DA. Since chitosan 
microspheres produced are bigger (115-150 µm) than desired, this system was considered not 
appropriate. The same trend regarding the influence of chitosan DA on microspheres 
morphology was observed with co-axial air stream system. Moreover, the air stream pressure 
is a preponderant factor in this system, with smaller particles being produced when air 
pressure is increased. Regarding aerodynamically driven system, the increase in the nozzle 
diameter of the equipment seems to lead to an increase in particles diameter. Moreover, by 
increasing the pressure smaller microspheres are produced. Flow rate was accordingly to the 
previous system not a relevant factor. Though co-axial air stream system presented some 
conditions within the diameter range expected, aerodynamically driven system was selected 
mainly due to its speed regarding particles production. 
Chitosan microspheres with an average diameter of 40 µm were successfully produced by 
ionotropic gelation with TPP coupled with coacervation using the aerodynamically driven 
system and chitosan of DA 6% and 0.5% (w/v) concentration under optimized conditions of 
0.5mL/min flow rate, 525 mBar air pressure and 0.25 mm nozzle.  
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Throughout the production process, microspheres were characterized by different 
equipments based on optical microscopy and laser diffraction. Optical microscopy was 
initially used to perform a qualitative analysis, giving information related with size and 
morphology of chitosan particles. IN Cell Analyzer equipment provided an automated 
approach to acquire high quality images and assess morphological parameters concerning 
each microsphere. In this equipment, an advanced analysis tool is coupled to the acquisition 
software allowing a thorough analysis of parameters as average diameter, maximum chord, 
area and form factor. Mastersizer particle sizing instrument uses the laser diffraction to 
measure particle size distribution. In this case, no images are provided, and thus, in order to 
assess morphology, one of the other techniques must be used. In conclusion, all three 
techniques provide complementary information, however depending on the purpose, a 
specific technique might be selected. 
Minimal genipin crosslinking was performed with a genipin concentration of 10 mM during 
45 minutes, only enough to avoid microspheres dissolution in acidic pH without losing their 
mucoadhesiveness. Following crosslinking, chitosan microspheres were lyophilised, presenting 
not only a different morphology but also a decrease in the average diameter when comparing 
to microspheres before lyophilisation. Chitosan microspheres present a more irregular 
structure, with an average diameter around 20 µm, but with a maximum chord around 50 µm. 
Optimization of the gastric mucosa labelling was performed using C57BL/6 mice fresh 
stomachs. Both nucleic acid and plasma membrane stains were employed with a better 
outcome associated with CellMask™ Deep Red stain, which can be applied to fresh stomachs 
without the need of previous fixation. Fixation of the mucosa followed by staining with DAPI 
also showed good results, though the use of fresh samples is preferable. Adhesion studies 
using the same models demonstrated that the developed chitosan microspheres have the 
ability to penetrate the gastric mucosa, which can be promising for future H. pylori removing 
assays. Regarding human gastric mucosa, few microspheres can be seen in deeper plans, 
suggesting that the microspheres have difficulty in penetrating, perhaps due to the thick 
layer of mucus observed over the surface of the mucosa.  
H. pylori adhesion to developed microspheres was evaluated at pH 6.0, and confirmed by 
incubation of previously fixed J99 H. pylori strain, labelled with FITC. When observed by 
CLSM, a spread adhesion of the bacteria to the chitosan microspheres is observed. The 
irregularity of the surface may indeed beneficiate the adhesion, since a higher surface area is 
available. Adhesion assays with live bacteria (only labelled with nucleic acid stains after 
adhesion to microspheres) did not allow drawing any conclusions, due to the auto-
fluorescence capability of chitosan microspheres. Therefore, further improvements need to 
be addressed regarding the labelling of the live bacteria, since it might be interesting to 
understand and evaluate the influence of bacteria being alive or fixed on the adhesion assay.  
In conclusion, the results suggest that chitosan microspheres have the potential to be 
used as binding system, demonstrating their ability to penetrate the gastric mucosa and 
adhere to J99 H. pylori strain.  
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Mucoadhesive effect of microspheres produced with chitosan with DA of 16%  
 
Because microparticles have more difficulty to penetrate through viscoelastic mucus layer 
than nanoparticles, an elevated number of positive charges (lower DA) could make the 
particles too mucoadhesive avoiding their penetration through the mucus layer.  
The production of microspheres with chitosan with DA of 16% in the VarJ30 could be 
therefore relevant to assure the benefits of using chitosan with a high or low DA. 
 
 
Live bacteria staining and bacteria adhesion quantification 
 
An alternative to the difficult observation of DNA staining would be to transform the 
bacteria with green GFP. While the amount of DNA of the bacteria remains the same, the GFP 
is replicated and therefore the signal becomes stronger. Also, and because of its higher 
amount, the contribution of the auto-fluorescence of the chitosan on the green range would 
be smaller, since the laser would not need to be so intense.  
Even regarding the quantification of the adhered bacteria this option could be interesting 
to assess. Image Stream is an imaging flow cytometer, combining the speed, sensitivity, and 
phenotyping abilities of flow cytometry with the detailed imagery and functional insights of 
microscopy. Since the equipment available at INEB only excites with the 488 nm laser, the 
detection of this protein would be facilitated when comparing to the DNA staining. 
Comparisons between fixed and live bacteria adhered to the chitosan microspheres could be 
performed.  
 
 
Study of chitosan microspheres ability to remove H. pylori from stomach fresh samples 
 
After evaluating the capability of chitosan microspheres to adhere to gastric mucosa and 
to H. pylori J99 strain, a system where all components interact should also be studied. 
Stomach samples should be infected with H. pylori, followed by incubation with developed 
chitosan microspheres.  
 
 
Immobilization of glycosylated receptors on chitosan microspheres surface 
 
Chitosan microspheres have shown to adhere to H. pylori due to only their mucoadhesive 
capacity. However, evaluating the influence on H. pylori adhesion of immobilized 
glycosylated receptors (Gly-R), such as Leb and sLex, on chitosan microspheres surface could 
be interesting.  
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